Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commision - Curevac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
European Commision - Astrazeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Aridis - PATH, Rotavirus Vaccine Development Agreement
2007
Biotechnology company
Product development partnership
Vaccine
Early clinical (through Phase 2)
UK Government - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Multinational pharmaceutical company
Vaccine
Commercialization
AUTM Model Inter-Institutional Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
DoD - Moderna, COVID-19, Vaccine Supply Agreement
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
BMGF - CureVac, Global Access Commitments Agreement
2015
Biotechnology company
Funder
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Biotechnology company
Funder
Multinational pharmaceutical company
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
General Industry
Device
Diagnostic
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
General Industry
Government
Other nonprofit
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
CEPI - CureVac, Framework Partnering Agreement
2019
Biotechnology company
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Biotechnology company
Multinational pharmaceutical company
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
WHO - Manufacturer, Ebola Products Collaboration LOA Template
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
EDCTP2 Policy on Clinical Trials Registration, Publication, and Data Sharing
2018
Funder
Device
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Multinational pharmaceutical company
Other nonprofit
Vaccine
Late clinical (Phase 3)
Commercialization
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Open Access Policy
2015
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Sample Grant Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Multinational pharmaceutical company
Pharmaceutical manufacturer
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation, Global Access Commitment & Humanitarian License Policy
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Biotechnology company
Government
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
General Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Merck- Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Biotechnology company
Multinational pharmaceutical company
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Multinational pharmaceutical company
Vaccine manufacturer
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP-BMS-Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Pharmaceutical manufacturer
Drug
Commercialization
MPP-BMS Sublicense & Tech Transfer Agreement
2017
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP - Gilead, TDF License Agreement
2011
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP - Pfizer, Sutezolid License Agreement
2019
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Other nonprofit
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP - ViiV, Dolutegravir License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Biotechnology company
Government
Vaccine
Preclinical
Commercialization
NIH - Non-Profit, License Agreement Template
2017
Government
Other nonprofit
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Biotechnology company
Funder
Vaccine manufacturer
Vaccine
Commercialization
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Pharmaceutical manufacturer
Vaccine manufacturer
Vaccine
Late clinical (Phase 3)
Commercialization
Pfizer/BioNTech-Dominican Republic Binding Term Sheet
2021
Biotechnology company
Government
Multinational pharmaceutical company
Vaccine
Late clinical (Phase 3)
Commercialization
Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
2021
Biotechnology company
Government
Multinational pharmaceutical company
Vaccine
Late clinical (Phase 3)
Commercialization
Academic Institution - Company, Redacted Research Collaboration Agreement Template
2016
Academic institution
General Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Regeneron - ATI, COVID-19 Antibodies Manufacturing Agreement
2020
Government
Pharmaceutical manufacturer
Drug
Late clinical (Phase 3)
Commercialization
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Multinational pharmaceutical company
Pharmaceutical manufacturer
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Confidential Disclosure Agreement Template
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
2021
Government
Multinational pharmaceutical company
Drug
Late clinical (Phase 3)
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => 
    [filters] => Array
        (
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
        )

    [text_agreement_args] => 
    [text_provision_args] => 
    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [s] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT   wpry_posts.* FROM wpry_posts  WHERE 1=1  AND wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')  ORDER BY wpry_posts.post_date DESC 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 3436
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:48:49
                            [post_date_gmt] => 2021-07-01 03:48:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 11:01:08
                            [post_modified_gmt] => 2021-07-22 11:01:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 3435
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:45:58
                            [post_date_gmt] => 2021-07-01 03:45:58
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:45:58
                            [post_modified_gmt] => 2021-07-01 03:45:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3435
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 3434
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:44:18
                            [post_date_gmt] => 2021-07-01 03:44:18
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:44:18
                            [post_modified_gmt] => 2021-07-01 03:44:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 3433
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:41:21
                            [post_date_gmt] => 2021-07-01 03:41:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:41:21
                            [post_modified_gmt] => 2021-07-01 03:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3431
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:38:49
                            [post_date_gmt] => 2021-07-01 03:38:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:38:49
                            [post_modified_gmt] => 2021-07-01 03:38:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 3430
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:27:51
                            [post_date_gmt] => 2021-07-01 03:27:51
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 13:58:20
                            [post_modified_gmt] => 2021-07-22 13:58:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 3428
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:24:00
                            [post_date_gmt] => 2021-07-01 03:24:00
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:24:00
                            [post_modified_gmt] => 2021-07-01 03:24:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3427
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:22:23
                            [post_date_gmt] => 2021-07-01 03:22:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:22:23
                            [post_modified_gmt] => 2021-07-01 03:22:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 3426
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:06:23
                            [post_date_gmt] => 2021-07-01 03:06:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:06:23
                            [post_modified_gmt] => 2021-07-01 03:06:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 3424
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:03:57
                            [post_date_gmt] => 2021-07-01 03:03:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 03:03:57
                            [post_modified_gmt] => 2021-07-01 03:03:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 3422
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:58:21
                            [post_date_gmt] => 2021-07-01 02:58:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 15:32:57
                            [post_modified_gmt] => 2021-07-22 15:32:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 3421
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:56:30
                            [post_date_gmt] => 2021-07-01 02:56:30
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 02:56:30
                            [post_modified_gmt] => 2021-07-01 02:56:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 3420
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:52:05
                            [post_date_gmt] => 2021-07-01 02:52:05
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 02:52:05
                            [post_modified_gmt] => 2021-07-01 02:52:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 3418
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:06:19
                            [post_date_gmt] => 2021-06-30 19:06:19
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 19:06:19
                            [post_modified_gmt] => 2021-06-30 19:06:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3418
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 3417
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:04:34
                            [post_date_gmt] => 2021-06-30 19:04:34
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 19:04:34
                            [post_modified_gmt] => 2021-06-30 19:04:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3417
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 3416
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:02:19
                            [post_date_gmt] => 2021-06-30 19:02:19
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 19:02:19
                            [post_modified_gmt] => 2021-06-30 19:02:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3416
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 3415
                            [post_author] => 5
                            [post_date] => 2021-06-30 19:00:20
                            [post_date_gmt] => 2021-06-30 19:00:20
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 19:00:20
                            [post_modified_gmt] => 2021-06-30 19:00:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3415
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 3414
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:54:43
                            [post_date_gmt] => 2021-06-30 18:54:43
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 12:51:17
                            [post_modified_gmt] => 2021-07-07 12:51:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3414
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 3413
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:52:08
                            [post_date_gmt] => 2021-06-30 18:52:08
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:52:08
                            [post_modified_gmt] => 2021-06-30 18:52:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3413
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 3412
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:48:13
                            [post_date_gmt] => 2021-06-30 18:48:13
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:48:13
                            [post_modified_gmt] => 2021-06-30 18:48:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3412
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 3411
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:39:53
                            [post_date_gmt] => 2021-06-30 18:39:53
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:39:53
                            [post_modified_gmt] => 2021-06-30 18:39:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3411
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 3410
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:37:02
                            [post_date_gmt] => 2021-06-30 18:37:02
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:44:47
                            [post_modified_gmt] => 2021-06-30 18:44:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3410
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 3409
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:34:04
                            [post_date_gmt] => 2021-06-30 18:34:04
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:34:04
                            [post_modified_gmt] => 2021-06-30 18:34:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3409
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 3407
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:29:55
                            [post_date_gmt] => 2021-06-30 18:29:55
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:29:55
                            [post_modified_gmt] => 2021-06-30 18:29:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3407
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 3406
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:25:58
                            [post_date_gmt] => 2021-06-30 18:25:58
                            [post_content] => 
                            [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 18:26:40
                            [post_modified_gmt] => 2021-06-30 18:26:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 3379
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:56:54
                            [post_date_gmt] => 2021-06-30 17:56:54
                            [post_content] => 
                            [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 17:56:54
                            [post_modified_gmt] => 2021-06-30 17:56:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3379
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 3378
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:55:17
                            [post_date_gmt] => 2021-06-30 17:55:17
                            [post_content] => 
                            [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 17:55:17
                            [post_modified_gmt] => 2021-06-30 17:55:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3378
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 3377
                            [post_author] => 5
                            [post_date] => 2021-06-30 17:20:14
                            [post_date_gmt] => 2021-06-30 17:20:14
                            [post_content] => 
                            [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 17:20:14
                            [post_modified_gmt] => 2021-06-30 17:20:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3377
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 3376
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:38:25
                            [post_date_gmt] => 2021-06-30 16:38:25
                            [post_content] => 
                            [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 16:38:25
                            [post_modified_gmt] => 2021-06-30 16:38:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3376
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 3375
                            [post_author] => 5
                            [post_date] => 2021-06-30 16:36:27
                            [post_date_gmt] => 2021-06-30 16:36:27
                            [post_content] => 
                            [post_title] => BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:06:55
                            [post_modified_gmt] => 2021-07-07 16:06:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3375
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 3369
                            [post_author] => 6
                            [post_date] => 2021-06-30 15:09:50
                            [post_date_gmt] => 2021-06-30 15:09:50
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:09:50
                            [post_modified_gmt] => 2021-06-30 15:09:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3369
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 3372
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:06:19
                            [post_date_gmt] => 2021-06-30 15:06:19
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:06:19
                            [post_modified_gmt] => 2021-06-30 15:06:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 3371
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:03:10
                            [post_date_gmt] => 2021-06-30 15:03:10
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:03:10
                            [post_modified_gmt] => 2021-06-30 15:03:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3371
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 3370
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:01:06
                            [post_date_gmt] => 2021-06-30 15:01:06
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 15:01:06
                            [post_modified_gmt] => 2021-06-30 15:01:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 3368
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:58:39
                            [post_date_gmt] => 2021-06-30 14:58:39
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:58:39
                            [post_modified_gmt] => 2021-06-30 14:58:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 3367
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:55:06
                            [post_date_gmt] => 2021-06-30 14:55:06
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 10:37:50
                            [post_modified_gmt] => 2021-07-21 10:37:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3367
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 3366
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:53:53
                            [post_date_gmt] => 2021-06-30 14:53:53
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:53:53
                            [post_modified_gmt] => 2021-06-30 14:53:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 3365
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:51:27
                            [post_date_gmt] => 2021-06-30 14:51:27
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:51:27
                            [post_modified_gmt] => 2021-06-30 14:51:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3365
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 3364
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:47:34
                            [post_date_gmt] => 2021-06-30 14:47:34
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:47:34
                            [post_modified_gmt] => 2021-06-30 14:47:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 3362
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:47:24
                            [post_date_gmt] => 2021-06-30 14:47:24
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 13:52:40
                            [post_modified_gmt] => 2021-07-21 13:52:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3362
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 3363
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:45:00
                            [post_date_gmt] => 2021-06-30 14:45:00
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:45:00
                            [post_modified_gmt] => 2021-06-30 14:45:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3363
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 3359
                            [post_author] => 6
                            [post_date] => 2021-06-30 14:38:46
                            [post_date_gmt] => 2021-06-30 14:38:46
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 13:04:43
                            [post_modified_gmt] => 2021-07-22 13:04:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3359
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 3361
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:30:51
                            [post_date_gmt] => 2021-06-30 14:30:51
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:30:51
                            [post_modified_gmt] => 2021-06-30 14:30:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 3360
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:28:40
                            [post_date_gmt] => 2021-06-30 14:28:40
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 14:28:40
                            [post_modified_gmt] => 2021-06-30 14:28:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 3356
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:53:23
                            [post_date_gmt] => 2021-06-30 13:53:23
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:53:23
                            [post_modified_gmt] => 2021-06-30 13:53:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 3358
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:47:23
                            [post_date_gmt] => 2021-06-30 13:47:23
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:47:23
                            [post_modified_gmt] => 2021-06-30 13:47:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3358
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 3357
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:41:11
                            [post_date_gmt] => 2021-06-30 13:41:11
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 13:20:28
                            [post_modified_gmt] => 2021-07-01 13:20:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3357
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 3355
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:30:36
                            [post_date_gmt] => 2021-06-30 13:30:36
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 13:21:49
                            [post_modified_gmt] => 2021-07-01 13:21:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3355
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 3354
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:29:21
                            [post_date_gmt] => 2021-06-30 13:29:21
                            [post_content] => 
                            [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:29:21
                            [post_modified_gmt] => 2021-06-30 13:29:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 3353
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:25:17
                            [post_date_gmt] => 2021-06-30 13:25:17
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:25:17
                            [post_modified_gmt] => 2021-06-30 13:25:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3353
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 3352
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:24:49
                            [post_date_gmt] => 2021-06-30 13:24:49
                            [post_content] => 
                            [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:24:49
                            [post_modified_gmt] => 2021-06-30 13:24:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 3350
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:18:18
                            [post_date_gmt] => 2021-06-30 13:18:18
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:18:18
                            [post_modified_gmt] => 2021-06-30 13:18:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3350
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 3347
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:12:31
                            [post_date_gmt] => 2021-06-30 13:12:31
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:14:40
                            [post_modified_gmt] => 2021-06-30 13:14:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3347
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 3346
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:07:59
                            [post_date_gmt] => 2021-06-30 13:07:59
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:07:59
                            [post_modified_gmt] => 2021-06-30 13:07:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3346
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 3345
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:04:52
                            [post_date_gmt] => 2021-06-30 13:04:52
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 13:19:28
                            [post_modified_gmt] => 2021-07-01 13:19:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3345
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 3344
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:02:36
                            [post_date_gmt] => 2021-06-30 13:02:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 13:03:45
                            [post_modified_gmt] => 2021-06-30 13:03:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 3343
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:57:07
                            [post_date_gmt] => 2021-06-30 12:57:07
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-21
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:57:07
                            [post_modified_gmt] => 2021-06-30 12:57:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 3342
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:50:17
                            [post_date_gmt] => 2021-06-30 12:50:17
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 10:15:57
                            [post_modified_gmt] => 2021-07-22 10:15:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 3341
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:44:43
                            [post_date_gmt] => 2021-06-30 12:44:43
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:44:43
                            [post_modified_gmt] => 2021-06-30 12:44:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 3340
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:39:34
                            [post_date_gmt] => 2021-06-30 12:39:34
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:39:34
                            [post_modified_gmt] => 2021-06-30 12:39:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3340
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 3339
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:37:28
                            [post_date_gmt] => 2021-06-30 12:37:28
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:37:28
                            [post_modified_gmt] => 2021-06-30 12:37:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 3338
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:27:08
                            [post_date_gmt] => 2021-06-30 12:27:08
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:32:08
                            [post_modified_gmt] => 2021-06-30 12:32:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 3337
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:21:58
                            [post_date_gmt] => 2021-06-30 12:21:58
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:22:26
                            [post_modified_gmt] => 2021-06-30 12:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3337
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 3335
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:20:18
                            [post_date_gmt] => 2021-06-30 12:20:18
                            [post_content] => 
                            [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-curevac-global-access-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-01 13:17:56
                            [post_modified_gmt] => 2021-07-01 13:17:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3335
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 3336
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:18:57
                            [post_date_gmt] => 2021-06-30 12:18:57
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:18:57
                            [post_modified_gmt] => 2021-06-30 12:18:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 3331
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:09:31
                            [post_date_gmt] => 2021-06-30 12:09:31
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:16:00
                            [post_modified_gmt] => 2021-06-30 12:16:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 3330
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:06:21
                            [post_date_gmt] => 2021-06-30 12:06:21
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 12:06:21
                            [post_modified_gmt] => 2021-06-30 12:06:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3330
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 3329
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:04:02
                            [post_date_gmt] => 2021-06-30 12:04:02
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-06 13:46:56
                            [post_modified_gmt] => 2021-07-06 13:46:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 3327
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:47:34
                            [post_date_gmt] => 2021-06-30 11:47:34
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-06 12:43:11
                            [post_modified_gmt] => 2021-07-06 12:43:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 3326
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:35:26
                            [post_date_gmt] => 2021-06-30 11:35:26
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 11:36:06
                            [post_modified_gmt] => 2021-06-30 11:36:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 3325
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:31:20
                            [post_date_gmt] => 2021-06-30 11:31:20
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 11:31:20
                            [post_modified_gmt] => 2021-06-30 11:31:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3325
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 3323
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:15:16
                            [post_date_gmt] => 2021-06-30 11:15:16
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 11:19:00
                            [post_modified_gmt] => 2021-06-30 11:19:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 3321
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:12:36
                            [post_date_gmt] => 2021-06-30 11:12:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 13-commercial-benefits-arising-from-commercial-use-13-3-use-of-product-in-affected-territory-only-cepi-intends-to-take-reasonable-efforts-to-ensure-that-the-products-will-be-utilized-in-the-affected
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 11:13:04
                            [post_modified_gmt] => 2021-06-30 11:13:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 3319
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:02:41
                            [post_date_gmt] => 2021-06-30 11:02:41
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 12:28:51
                            [post_modified_gmt] => 2021-07-07 12:28:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3319
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 3318
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:46:25
                            [post_date_gmt] => 2021-06-30 10:46:25
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:46:25
                            [post_modified_gmt] => 2021-06-30 10:46:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 3317
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:29:34
                            [post_date_gmt] => 2021-06-30 10:29:34
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:29:34
                            [post_modified_gmt] => 2021-06-30 10:29:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3317
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 3316
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:25:45
                            [post_date_gmt] => 2021-06-30 10:25:45
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-06 13:50:34
                            [post_modified_gmt] => 2021-07-06 13:50:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 3315
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:19:01
                            [post_date_gmt] => 2021-06-30 10:19:01
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:19:01
                            [post_modified_gmt] => 2021-06-30 10:19:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 3312
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:06:34
                            [post_date_gmt] => 2021-06-30 10:06:34
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:06:34
                            [post_modified_gmt] => 2021-06-30 10:06:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 3311
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:04:32
                            [post_date_gmt] => 2021-06-30 10:04:32
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:04:32
                            [post_modified_gmt] => 2021-06-30 10:04:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 3310
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:01:40
                            [post_date_gmt] => 2021-06-30 10:01:40
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 10:01:40
                            [post_modified_gmt] => 2021-06-30 10:01:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3310
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 3309
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:51:28
                            [post_date_gmt] => 2021-06-30 09:51:28
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:51:28
                            [post_modified_gmt] => 2021-06-30 09:51:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3309
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 3308
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:48:24
                            [post_date_gmt] => 2021-06-30 09:48:24
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:48:24
                            [post_modified_gmt] => 2021-06-30 09:48:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3308
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 3307
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:44:19
                            [post_date_gmt] => 2021-06-30 09:44:19
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:45:07
                            [post_modified_gmt] => 2021-06-30 09:45:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3307
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 3305
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:35:10
                            [post_date_gmt] => 2021-06-30 09:35:10
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-06 11:48:57
                            [post_modified_gmt] => 2021-07-06 11:48:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3305
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 3304
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:30:56
                            [post_date_gmt] => 2021-06-30 09:30:56
                            [post_content] => 
                            [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:30:56
                            [post_modified_gmt] => 2021-06-30 09:30:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3304
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 3303
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:26:40
                            [post_date_gmt] => 2021-06-30 09:26:40
                            [post_content] => 
                            [post_title] => UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:26:40
                            [post_modified_gmt] => 2021-06-30 09:26:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3303
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 3302
                            [post_author] => 6
                            [post_date] => 2021-06-30 09:21:45
                            [post_date_gmt] => 2021-06-30 09:21:45
                            [post_content] => 
                            [post_title] => UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 3302
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-30 09:26:51
                            [post_modified_gmt] => 2021-06-30 09:26:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3302
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 3221
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:23:49
                            [post_date_gmt] => 2021-06-28 12:23:49
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:23:49
                            [post_modified_gmt] => 2021-06-28 12:23:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 3220
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:22:09
                            [post_date_gmt] => 2021-06-28 12:22:09
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:22:09
                            [post_modified_gmt] => 2021-06-28 12:22:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 3219
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:19:29
                            [post_date_gmt] => 2021-06-28 12:19:29
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:19:29
                            [post_modified_gmt] => 2021-06-28 12:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 3218
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:16:20
                            [post_date_gmt] => 2021-06-28 12:16:20
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:16:20
                            [post_modified_gmt] => 2021-06-28 12:16:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 3217
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:14:37
                            [post_date_gmt] => 2021-06-28 12:14:37
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:14:37
                            [post_modified_gmt] => 2021-06-28 12:14:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 3216
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:11:22
                            [post_date_gmt] => 2021-06-28 12:11:22
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:11:22
                            [post_modified_gmt] => 2021-06-28 12:11:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 3215
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:07:55
                            [post_date_gmt] => 2021-06-28 12:07:55
                            [post_content] => 
                            [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-28 12:07:55
                            [post_modified_gmt] => 2021-06-28 12:07:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 3211
                            [post_author] => 5
                            [post_date] => 2021-06-22 08:43:07
                            [post_date_gmt] => 2021-06-22 08:43:07
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:43:07
                            [post_modified_gmt] => 2021-06-22 08:43:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3211
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 3127
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:08:41
                            [post_date_gmt] => 2021-06-03 15:08:41
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:02
                            [post_modified_gmt] => 2021-06-04 08:01:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 3126
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:05:40
                            [post_date_gmt] => 2021-06-03 15:05:40
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:29
                            [post_modified_gmt] => 2021-06-04 08:01:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 3125
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:03:17
                            [post_date_gmt] => 2021-06-03 15:03:17
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:01:54
                            [post_modified_gmt] => 2021-06-04 08:01:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 3124
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:01:23
                            [post_date_gmt] => 2021-06-03 15:01:23
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:02:32
                            [post_modified_gmt] => 2021-06-04 08:02:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 3123
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:51:22
                            [post_date_gmt] => 2021-06-03 14:51:22
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 12:37:50
                            [post_modified_gmt] => 2021-07-21 12:37:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 3122
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:45:44
                            [post_date_gmt] => 2021-06-03 14:45:44
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:05:37
                            [post_modified_gmt] => 2021-06-04 08:05:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 3121
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:26:32
                            [post_date_gmt] => 2021-06-03 14:26:32
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:09:56
                            [post_modified_gmt] => 2021-06-04 08:09:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 3120
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:24:03
                            [post_date_gmt] => 2021-06-03 14:24:03
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 08:13:26
                            [post_modified_gmt] => 2021-06-04 08:13:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 3119
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:21:50
                            [post_date_gmt] => 2021-06-03 14:21:50
                            [post_content] => 
                            [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 13:54:22
                            [post_modified_gmt] => 2021-06-07 13:54:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 2972
                            [post_author] => 5
                            [post_date] => 2021-06-01 10:17:19
                            [post_date_gmt] => 2021-06-01 10:17:19
                            [post_content] => 
                            [post_title] => WHO Template Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 10:17:19
                            [post_modified_gmt] => 2021-06-01 10:17:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2972
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 2956
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:56:15
                            [post_date_gmt] => 2021-05-28 18:56:15
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 08:49:49
                            [post_modified_gmt] => 2021-06-02 08:49:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2956
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 2961
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:47
                            [post_date_gmt] => 2021-05-28 18:55:47
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 09:23:30
                            [post_modified_gmt] => 2021-06-02 09:23:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2961
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 2965
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:12
                            [post_date_gmt] => 2021-05-28 18:55:12
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 13:00:56
                            [post_modified_gmt] => 2021-06-08 13:00:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2965
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 2947
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:54:17
                            [post_date_gmt] => 2021-05-28 18:54:17
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 08:16:41
                            [post_modified_gmt] => 2021-06-02 08:16:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 2960
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:36
                            [post_date_gmt] => 2021-05-28 18:53:36
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 09:21:06
                            [post_modified_gmt] => 2021-06-02 09:21:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2960
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 2964
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:11
                            [post_date_gmt] => 2021-05-28 18:53:11
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 08:02:13
                            [post_modified_gmt] => 2021-06-02 08:02:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2964
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 2958
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:54
                            [post_date_gmt] => 2021-05-28 18:52:54
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 09:14:15
                            [post_modified_gmt] => 2021-06-02 09:14:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2958
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 2949
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:06
                            [post_date_gmt] => 2021-05-28 18:52:06
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-23 13:13:35
                            [post_modified_gmt] => 2021-06-23 13:13:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2949
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 2957
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:51:39
                            [post_date_gmt] => 2021-05-28 18:51:39
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 09:09:58
                            [post_modified_gmt] => 2021-06-02 09:09:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2957
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 2962
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:50:18
                            [post_date_gmt] => 2021-05-28 18:50:18
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 09:19:22
                            [post_modified_gmt] => 2021-06-02 09:19:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 2945
                            [post_author] => 6
                            [post_date] => 2021-05-28 14:03:27
                            [post_date_gmt] => 2021-05-28 14:03:27
                            [post_content] => 
                            [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 08:51:28
                            [post_modified_gmt] => 2021-06-02 08:51:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2945
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 15:39:30
                            [post_modified_gmt] => 2021-06-16 15:39:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 12:18:00
                            [post_modified_gmt] => 2021-07-21 12:18:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 14:10:32
                            [post_modified_gmt] => 2021-07-22 14:10:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 08:56:01
                            [post_modified_gmt] => 2021-06-21 08:56:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 15:13:39
                            [post_modified_gmt] => 2021-06-02 15:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 12:49:25
                            [post_modified_gmt] => 2021-06-08 12:49:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 19:09:07
                            [post_modified_gmt] => 2021-05-14 19:09:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 2888
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:01:08
                            [post_date_gmt] => 2021-05-14 19:01:08
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-20 12:23:46
                            [post_modified_gmt] => 2021-05-20 12:23:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2888
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 2886
                            [post_author] => 6
                            [post_date] => 2021-05-14 18:21:24
                            [post_date_gmt] => 2021-05-14 18:21:24
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 18:21:24
                            [post_modified_gmt] => 2021-05-14 18:21:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 18:17:37
                            [post_modified_gmt] => 2021-05-14 18:17:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 2873
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:17:08
                            [post_date_gmt] => 2021-05-11 15:17:08
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-26 08:35:05
                            [post_modified_gmt] => 2021-05-26 08:35:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 2872
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:14:24
                            [post_date_gmt] => 2021-05-11 15:14:24
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 14:35:52
                            [post_modified_gmt] => 2021-06-07 14:35:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 2870
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:07:59
                            [post_date_gmt] => 2021-05-11 15:07:59
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-15 09:15:21
                            [post_modified_gmt] => 2021-06-15 09:15:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 2869
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:53:04
                            [post_date_gmt] => 2021-05-11 14:53:04
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:15:00
                            [post_modified_gmt] => 2021-05-14 09:15:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 2868
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:44:06
                            [post_date_gmt] => 2021-05-11 14:44:06
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:26:33
                            [post_modified_gmt] => 2021-05-14 09:26:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2868
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 2867
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:28:02
                            [post_date_gmt] => 2021-05-11 14:28:02
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2867
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:21:28
                            [post_modified_gmt] => 2021-06-01 09:21:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 2865
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:25:05
                            [post_date_gmt] => 2021-05-11 14:25:05
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-14 09:48:01
                            [post_modified_gmt] => 2021-05-14 09:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2865
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:39:49
                            [post_modified_gmt] => 2021-04-16 16:39:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 2823
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:17:11
                            [post_date_gmt] => 2021-04-16 16:17:11
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:17:11
                            [post_modified_gmt] => 2021-04-16 16:17:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 16:09:31
                            [post_modified_gmt] => 2021-04-16 16:09:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 2821
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:55:04
                            [post_date_gmt] => 2021-04-16 12:55:04
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 12:55:04
                            [post_modified_gmt] => 2021-04-16 12:55:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2821
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 2820
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:44:14
                            [post_date_gmt] => 2021-04-16 12:44:14
                            [post_content] => 
                            [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 11:55:37
                            [post_modified_gmt] => 2021-05-28 11:55:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 2819
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:12:32
                            [post_date_gmt] => 2021-04-16 12:12:32
                            [post_content] => 
                            [post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-04-16 12:15:57
                            [post_modified_gmt] => 2021-04-16 12:15:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2819
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:21
                            [post_modified_gmt] => 2021-05-17 13:21:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:43:25
                            [post_modified_gmt] => 2021-06-01 09:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:40
                            [post_modified_gmt] => 2021-05-17 13:21:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 2740
                            [post_author] => 5
                            [post_date] => 2021-03-30 14:54:54
                            [post_date_gmt] => 2021-03-30 14:54:54
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:21:50
                            [post_modified_gmt] => 2021-05-17 13:21:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:13
                            [post_modified_gmt] => 2021-05-17 13:22:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 14:14:47
                            [post_modified_gmt] => 2021-07-22 14:14:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:24
                            [post_modified_gmt] => 2021-05-17 13:22:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:22:33
                            [post_modified_gmt] => 2021-05-17 13:22:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 2738
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:04:24
                            [post_date_gmt] => 2021-03-24 13:04:24
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:03:59
                            [post_modified_gmt] => 2021-06-09 09:03:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:04
                            [post_modified_gmt] => 2021-05-17 13:23:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:17
                            [post_modified_gmt] => 2021-05-17 13:23:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 2735
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:05:28
                            [post_date_gmt] => 2021-03-23 18:05:28
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:23:28
                            [post_modified_gmt] => 2021-05-17 13:23:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 17:12:58
                            [post_modified_gmt] => 2021-06-07 17:12:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 2543
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:15:58
                            [post_date_gmt] => 2021-03-12 18:15:58
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:24:40
                            [post_modified_gmt] => 2021-05-17 13:24:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 2540
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:12:48
                            [post_date_gmt] => 2021-03-12 18:12:48
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 13:52:44
                            [post_modified_gmt] => 2021-07-07 13:52:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 2541
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:11:14
                            [post_date_gmt] => 2021-03-12 18:11:14
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 16:06:34
                            [post_modified_gmt] => 2021-05-28 16:06:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 2542
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:21:07
                            [post_date_gmt] => 2021-03-12 14:21:07
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 15:59:01
                            [post_modified_gmt] => 2021-05-28 15:59:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 2544
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:16:06
                            [post_date_gmt] => 2021-03-12 14:16:06
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:14
                            [post_modified_gmt] => 2021-05-17 13:25:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 2545
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:14:38
                            [post_date_gmt] => 2021-03-12 14:14:38
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:23
                            [post_modified_gmt] => 2021-05-17 13:25:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 2546
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:13:16
                            [post_date_gmt] => 2021-03-12 14:13:16
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:35
                            [post_modified_gmt] => 2021-05-17 13:25:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 2547
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:58:55
                            [post_date_gmt] => 2021-03-12 13:58:55
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 10:39:30
                            [post_modified_gmt] => 2021-07-21 10:39:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 2548
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:55:59
                            [post_date_gmt] => 2021-03-12 13:55:59
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-04 09:42:06
                            [post_modified_gmt] => 2021-06-04 09:42:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 2549
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:50:41
                            [post_date_gmt] => 2021-03-12 13:50:41
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:25:58
                            [post_modified_gmt] => 2021-05-17 13:25:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 16:09:05
                            [post_modified_gmt] => 2021-05-28 16:09:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 2554
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:44:47
                            [post_date_gmt] => 2021-03-12 13:44:47
                            [post_content] => 
                            [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:26:22
                            [post_modified_gmt] => 2021-05-17 13:26:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:09:35
                            [post_modified_gmt] => 2021-05-17 13:09:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 2459
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:31
                            [post_date_gmt] => 2021-02-25 15:25:31
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:50:06
                            [post_modified_gmt] => 2021-06-01 09:50:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 2460
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:51
                            [post_date_gmt] => 2021-02-25 15:23:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:51
                            [post_modified_gmt] => 2021-02-25 15:23:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:35
                            [post_modified_gmt] => 2021-02-25 15:23:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:23:19
                            [post_modified_gmt] => 2021-02-25 15:23:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:55:43
                            [post_modified_gmt] => 2021-06-01 09:55:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:21:51
                            [post_modified_gmt] => 2021-02-25 15:21:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 10:25:45
                            [post_modified_gmt] => 2021-05-27 10:25:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 14:59:57
                            [post_modified_gmt] => 2021-06-21 14:59:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-02-25 15:20:15
                            [post_modified_gmt] => 2021-02-25 15:20:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 2470
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:24:13
                            [post_date_gmt] => 2021-01-25 13:24:13
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:26:57
                            [post_modified_gmt] => 2021-05-17 13:26:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 2472
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:23:03
                            [post_date_gmt] => 2021-01-25 13:23:03
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:05
                            [post_modified_gmt] => 2021-05-17 13:27:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 2473
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:21:58
                            [post_date_gmt] => 2021-01-25 13:21:58
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:13
                            [post_modified_gmt] => 2021-05-17 13:27:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 2474
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:19:34
                            [post_date_gmt] => 2021-01-25 13:19:34
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 11:53:52
                            [post_modified_gmt] => 2021-07-22 11:53:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 2475
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:53
                            [post_date_gmt] => 2021-01-25 13:18:53
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:28
                            [post_modified_gmt] => 2021-05-17 13:27:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 2476
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:09
                            [post_date_gmt] => 2021-01-25 13:18:09
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:36
                            [post_modified_gmt] => 2021-05-17 13:27:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 2477
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:16:23
                            [post_date_gmt] => 2021-01-25 13:16:23
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:27:44
                            [post_modified_gmt] => 2021-05-17 13:27:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 2478
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:14:33
                            [post_date_gmt] => 2021-01-25 13:14:33
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 11:31:53
                            [post_modified_gmt] => 2021-06-17 11:31:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 2479
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:12:32
                            [post_date_gmt] => 2021-01-25 13:12:32
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 17:33:15
                            [post_modified_gmt] => 2021-06-01 17:33:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 2480
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:47
                            [post_date_gmt] => 2021-01-25 13:11:47
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:28:03
                            [post_modified_gmt] => 2021-05-17 13:28:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 2481
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:08
                            [post_date_gmt] => 2021-01-25 13:11:08
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 09:53:25
                            [post_modified_gmt] => 2021-06-17 09:53:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 15:58:24
                            [post_modified_gmt] => 2021-06-16 15:58:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 2483
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:51
                            [post_date_gmt] => 2021-01-25 13:08:51
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-17 13:28:30
                            [post_modified_gmt] => 2021-05-17 13:28:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 2471
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:02
                            [post_date_gmt] => 2021-01-25 13:08:02
                            [post_content] => 
                            [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-10 10:15:54
                            [post_modified_gmt] => 2021-06-10 10:15:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 2454
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:44:16
                            [post_date_gmt] => 2021-01-19 11:44:16
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:43:04
                            [post_modified_gmt] => 2021-05-27 09:43:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 2452
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:41:19
                            [post_date_gmt] => 2021-01-19 11:41:19
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-02 12:14:43
                            [post_modified_gmt] => 2021-06-02 12:14:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 2450
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:04:23
                            [post_date_gmt] => 2021-01-19 11:04:23
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:47:15
                            [post_modified_gmt] => 2021-05-27 09:47:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 2449
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:47:27
                            [post_date_gmt] => 2021-01-19 10:47:27
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:47:52
                            [post_modified_gmt] => 2021-05-27 09:47:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 2448
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:24:45
                            [post_date_gmt] => 2021-01-19 10:24:45
                            [post_content] => 
                            [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:49:00
                            [post_modified_gmt] => 2021-05-27 09:49:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 2445
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:31:14
                            [post_date_gmt] => 2021-01-19 09:31:14
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 08:28:27
                            [post_modified_gmt] => 2021-07-07 08:28:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:33:58
                            [post_modified_gmt] => 2021-05-27 09:33:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:34:37
                            [post_modified_gmt] => 2021-05-27 09:34:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 08:30:33
                            [post_modified_gmt] => 2021-07-07 08:30:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:36:53
                            [post_modified_gmt] => 2021-05-27 09:36:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 2440
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:45:33
                            [post_date_gmt] => 2021-01-19 06:45:33
                            [post_content] => 
                            [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-27 09:37:25
                            [post_modified_gmt] => 2021-05-27 09:37:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 2425
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:33
                            [post_date_gmt] => 2020-12-14 15:02:33
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-01-22 12:13:42
                            [post_modified_gmt] => 2021-01-22 12:13:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 18:47:49
                            [post_modified_gmt] => 2021-06-01 18:47:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 08:18:09
                            [post_modified_gmt] => 2021-06-09 08:18:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 2422
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:29
                            [post_date_gmt] => 2020-12-14 14:59:29
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 11:33:16
                            [post_modified_gmt] => 2021-06-21 11:33:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 1395
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:25:33
                            [post_date_gmt] => 2020-05-30 21:25:33
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:28:33
                            [post_modified_gmt] => 2020-08-06 08:28:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 1394
                            [post_author] => 7
                            [post_date] => 2020-05-30 21:22:44
                            [post_date_gmt] => 2020-05-30 21:22:44
                            [post_content] => 
                            [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:20:23
                            [post_modified_gmt] => 2021-06-09 09:20:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 1393
                            [post_author] => 7
                            [post_date] => 2020-05-30 20:13:50
                            [post_date_gmt] => 2020-05-30 20:13:50
                            [post_content] => 
                            [post_title] => Gates Foundation Open Access Policy
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 1393
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 15:44:36
                            [post_modified_gmt] => 2021-06-08 15:44:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 1315
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:56:03
                            [post_date_gmt] => 2020-05-23 17:56:03
                            [post_content] => 
                            [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 12:02:04
                            [post_modified_gmt] => 2021-07-21 12:02:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 1313
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:55:00
                            [post_date_gmt] => 2020-05-23 17:55:00
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:26:38
                            [post_modified_gmt] => 2021-07-21 11:26:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 1314
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:54:57
                            [post_date_gmt] => 2020-05-23 17:54:57
                            [post_content] => 
                            [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:28:48
                            [post_modified_gmt] => 2021-07-21 11:28:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 1308
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:17:48
                            [post_date_gmt] => 2020-05-23 17:17:48
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 09:45:37
                            [post_modified_gmt] => 2021-06-22 09:45:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 1309
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:17:44
                            [post_date_gmt] => 2020-05-23 17:17:44
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking  Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2joint-undertaking-model-consortium-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:28:41
                            [post_modified_gmt] => 2021-06-21 13:28:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 1307
                            [post_author] => 7
                            [post_date] => 2020-05-23 17:05:21
                            [post_date_gmt] => 2020-05-23 17:05:21
                            [post_content] => 
                            [post_title] => IMI 2 Model Consortium Agreement & Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:02:13
                            [post_modified_gmt] => 2021-06-21 13:02:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 1306
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:57:14
                            [post_date_gmt] => 2020-05-23 16:57:14
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:04:57
                            [post_modified_gmt] => 2021-06-21 13:04:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 1305
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:51:40
                            [post_date_gmt] => 2020-05-23 16:51:40
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 1305
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:23:38
                            [post_modified_gmt] => 2021-06-21 13:23:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 1304
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:46:37
                            [post_date_gmt] => 2020-05-23 16:46:37
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:41:52
                            [post_modified_gmt] => 2021-06-21 13:41:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 1303
                            [post_author] => 7
                            [post_date] => 2020-05-23 16:46:30
                            [post_date_gmt] => 2020-05-23 16:46:30
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 09:58:35
                            [post_modified_gmt] => 2021-06-22 09:58:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 1296
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:46:47
                            [post_date_gmt] => 2020-05-22 23:46:47
                            [post_content] => 
                            [post_title] => Summary of Provisions from WHO Template Agreements
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 11:05:19
                            [post_modified_gmt] => 2021-06-22 11:05:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 1291
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:42:19
                            [post_date_gmt] => 2020-05-22 23:42:19
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 11:42:27
                            [post_modified_gmt] => 2021-06-07 11:42:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 1293
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:42:02
                            [post_date_gmt] => 2020-05-22 23:42:02
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-15 08:02:02
                            [post_modified_gmt] => 2021-06-15 08:02:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 1288
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:31:30
                            [post_date_gmt] => 2020-05-22 23:31:30
                            [post_content] => 
                            [post_title] => IMI 2 Model Consortium Agreement & Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:05:44
                            [post_modified_gmt] => 2021-06-22 08:05:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 1287
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:05:30
                            [post_date_gmt] => 2020-05-22 23:05:30
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:02:51
                            [post_modified_gmt] => 2021-07-21 11:02:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 1285
                            [post_author] => 6
                            [post_date] => 2020-05-22 23:01:07
                            [post_date_gmt] => 2020-05-22 23:01:07
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:03:29
                            [post_modified_gmt] => 2021-07-21 11:03:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 1284
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:58:55
                            [post_date_gmt] => 2020-05-22 22:58:55
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 14:49:53
                            [post_modified_gmt] => 2021-06-16 14:49:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 1283
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:57:44
                            [post_date_gmt] => 2020-05-22 22:57:44
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:56:15
                            [post_modified_gmt] => 2020-08-06 05:56:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 1282
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:56:18
                            [post_date_gmt] => 2020-05-22 22:56:18
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 09:47:34
                            [post_modified_gmt] => 2021-06-01 09:47:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 1281
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:55:22
                            [post_date_gmt] => 2020-05-22 22:55:22
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:57:24
                            [post_modified_gmt] => 2020-08-06 05:57:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 1280
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:54:32
                            [post_date_gmt] => 2020-05-22 22:54:32
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 08:04:56
                            [post_modified_gmt] => 2021-06-09 08:04:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 1276
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:40:34
                            [post_date_gmt] => 2020-05-22 22:40:34
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:03:41
                            [post_modified_gmt] => 2021-07-21 11:03:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 1275
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:39:41
                            [post_date_gmt] => 2020-05-22 22:39:41
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 14:18:04
                            [post_modified_gmt] => 2021-05-28 14:18:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 1274
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:38:47
                            [post_date_gmt] => 2020-05-22 22:38:47
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 05:59:08
                            [post_modified_gmt] => 2020-08-06 05:59:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 1273
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:37:54
                            [post_date_gmt] => 2020-05-22 22:37:54
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 04:20:47
                            [post_modified_gmt] => 2020-08-04 04:20:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 1272
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:36:39
                            [post_date_gmt] => 2020-05-22 22:36:39
                            [post_content] => 
                            [post_title] => BU Startup Exclusive License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 10:58:45
                            [post_modified_gmt] => 2021-07-22 10:58:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 1271
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:34:12
                            [post_date_gmt] => 2020-05-22 22:34:12
                            [post_content] => 
                            [post_title] => WHO Standard Framework Memorandum of Understanding
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-standard-framework-memorandum-of-understanding-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 10:14:31
                            [post_modified_gmt] => 2021-06-01 10:14:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 1270
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:32:29
                            [post_date_gmt] => 2020-05-22 22:32:29
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-10-18 11:46:22
                            [post_modified_gmt] => 2020-10-18 11:46:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 1269
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:29:54
                            [post_date_gmt] => 2020-05-22 22:29:54
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:01:05
                            [post_modified_gmt] => 2020-08-06 06:01:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 1268
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:27:54
                            [post_date_gmt] => 2020-05-22 22:27:54
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 10:42:12
                            [post_modified_gmt] => 2021-06-22 10:42:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 1267
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:26:39
                            [post_date_gmt] => 2020-05-22 22:26:39
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:18:15
                            [post_modified_gmt] => 2021-07-21 11:18:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 1266
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:25:16
                            [post_date_gmt] => 2020-05-22 22:25:16
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:00:55
                            [post_modified_gmt] => 2021-06-22 08:00:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 1265
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:24:11
                            [post_date_gmt] => 2020-05-22 22:24:11
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 11:02:34
                            [post_modified_gmt] => 2021-06-01 11:02:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 1264
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:22:55
                            [post_date_gmt] => 2020-05-22 22:22:55
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 11:09:14
                            [post_modified_gmt] => 2021-05-28 11:09:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 1263
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:20:56
                            [post_date_gmt] => 2020-05-22 22:20:56
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:56:20
                            [post_modified_gmt] => 2021-07-21 11:56:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 1262
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:18:41
                            [post_date_gmt] => 2020-05-22 22:18:41
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 11:05:58
                            [post_modified_gmt] => 2021-06-07 11:05:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 1261
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:17:34
                            [post_date_gmt] => 2020-05-22 22:17:34
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:02:17
                            [post_modified_gmt] => 2021-06-22 08:02:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 1259
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:04:31
                            [post_date_gmt] => 2020-05-22 22:04:31
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:06:50
                            [post_modified_gmt] => 2020-08-06 06:06:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 1258
                            [post_author] => 6
                            [post_date] => 2020-05-22 22:03:08
                            [post_date_gmt] => 2020-05-22 22:03:08
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-22 14:03:39
                            [post_modified_gmt] => 2021-07-22 14:03:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 1257
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:54:08
                            [post_date_gmt] => 2020-05-22 21:54:08
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 10:59:58
                            [post_modified_gmt] => 2021-06-07 10:59:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 1255
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:49:26
                            [post_date_gmt] => 2020-05-22 21:49:26
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 11:56:13
                            [post_modified_gmt] => 2021-06-17 11:56:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 1254
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:44:49
                            [post_date_gmt] => 2020-05-22 21:44:49
                            [post_content] => 
                            [post_title] => Gates Foundation Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-data-materials-sharing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:09:56
                            [post_modified_gmt] => 2020-08-06 06:09:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 1253
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:42:28
                            [post_date_gmt] => 2020-05-22 21:42:28
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:08:14
                            [post_modified_gmt] => 2021-06-22 08:08:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 1252
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:41:17
                            [post_date_gmt] => 2020-05-22 21:41:17
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 13:40:39
                            [post_modified_gmt] => 2021-05-28 13:40:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 1251
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:39:48
                            [post_date_gmt] => 2020-05-22 21:39:48
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:40:50
                            [post_modified_gmt] => 2020-08-06 19:40:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 1250
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:38:31
                            [post_date_gmt] => 2020-05-22 21:38:31
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 19:41:55
                            [post_modified_gmt] => 2020-08-06 19:41:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 1249
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:37:42
                            [post_date_gmt] => 2020-05-22 21:37:42
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:22:26
                            [post_modified_gmt] => 2020-08-06 06:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 1248
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:36:47
                            [post_date_gmt] => 2020-05-22 21:36:47
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:19:18
                            [post_modified_gmt] => 2020-08-06 06:19:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 1247
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:33:54
                            [post_date_gmt] => 2020-05-22 21:33:54
                            [post_content] => 
                            [post_title] => WHO Mutual Confidential Disclosure Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-mutual-confidential-disclosure-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-10 11:25:18
                            [post_modified_gmt] => 2021-06-10 11:25:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 1245
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:32:14
                            [post_date_gmt] => 2020-05-22 21:32:14
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 14:50:49
                            [post_modified_gmt] => 2021-06-17 14:50:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 1243
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:29:10
                            [post_date_gmt] => 2020-05-22 21:29:10
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:15:56
                            [post_modified_gmt] => 2020-08-06 06:15:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 1242
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:26:04
                            [post_date_gmt] => 2020-05-22 21:26:04
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:03:53
                            [post_modified_gmt] => 2021-07-21 11:03:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 1240
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:22:47
                            [post_date_gmt] => 2020-05-22 21:22:47
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 18:39:45
                            [post_modified_gmt] => 2021-06-01 18:39:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 1239
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:21:49
                            [post_date_gmt] => 2020-05-22 21:21:49
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 13:42:45
                            [post_modified_gmt] => 2021-06-07 13:42:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 1238
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:20:51
                            [post_date_gmt] => 2020-05-22 21:20:51
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 14:00:56
                            [post_modified_gmt] => 2021-06-08 14:00:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 1237
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:19:08
                            [post_date_gmt] => 2020-05-22 21:19:08
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:10:16
                            [post_modified_gmt] => 2021-06-21 13:10:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 1235
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:01:14
                            [post_date_gmt] => 2020-05-22 21:01:14
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:04:08
                            [post_modified_gmt] => 2021-07-21 11:04:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 1233
                            [post_author] => 6
                            [post_date] => 2020-05-22 21:00:08
                            [post_date_gmt] => 2020-05-22 21:00:08
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 13:58:18
                            [post_modified_gmt] => 2021-06-08 13:58:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 1232
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:57:46
                            [post_date_gmt] => 2020-05-22 20:57:46
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 09:30:36
                            [post_modified_gmt] => 2021-06-21 09:30:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 1231
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:54:50
                            [post_date_gmt] => 2020-05-22 20:54:50
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 06:37:41
                            [post_modified_gmt] => 2020-08-06 06:37:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 1229
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:51:35
                            [post_date_gmt] => 2020-05-22 20:51:35
                            [post_content] => 
                            [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 11:52:06
                            [post_modified_gmt] => 2021-06-21 11:52:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 1228
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:49:20
                            [post_date_gmt] => 2020-05-22 20:49:20
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 12:03:38
                            [post_modified_gmt] => 2021-06-21 12:03:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 1227
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:48:27
                            [post_date_gmt] => 2020-05-22 20:48:27
                            [post_content] => 
                            [post_title] => Ebola WHO-Manufacturer LOA (Annex)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ebola-who-manufacturer-loa-annex
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-06 13:55:12
                            [post_modified_gmt] => 2021-07-06 13:55:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 1226
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:47:05
                            [post_date_gmt] => 2020-05-22 20:47:05
                            [post_content] => 
                            [post_title] => WHO Template Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 09:49:13
                            [post_modified_gmt] => 2021-06-21 09:49:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 1225
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:43:20
                            [post_date_gmt] => 2020-05-22 20:43:20
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-10 12:10:21
                            [post_modified_gmt] => 2021-06-10 12:10:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 1222
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:12:04
                            [post_date_gmt] => 2020-05-22 20:12:04
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 12:52:26
                            [post_modified_gmt] => 2021-06-17 12:52:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 1221
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:09:53
                            [post_date_gmt] => 2020-05-22 20:09:53
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 15:41:03
                            [post_modified_gmt] => 2021-06-08 15:41:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 1220
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:05:59
                            [post_date_gmt] => 2020-05-22 20:05:59
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 15:06:36
                            [post_modified_gmt] => 2021-05-28 15:06:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 1218
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:04:53
                            [post_date_gmt] => 2020-05-22 20:04:53
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 15:32:44
                            [post_modified_gmt] => 2021-06-08 15:32:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 1217
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:00:26
                            [post_date_gmt] => 2020-05-22 20:00:26
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:34:18
                            [post_modified_gmt] => 2021-06-09 09:34:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 1216
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:58:08
                            [post_date_gmt] => 2020-05-22 19:58:08
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:19:32
                            [post_modified_gmt] => 2021-06-09 09:19:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 1215
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:56:47
                            [post_date_gmt] => 2020-05-22 19:56:47
                            [post_content] => 
                            [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => edctp2-policy-on-clinical-trials-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-08 15:42:31
                            [post_modified_gmt] => 2021-06-08 15:42:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 1214
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:55:41
                            [post_date_gmt] => 2020-05-22 19:55:41
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:21:17
                            [post_modified_gmt] => 2021-06-09 09:21:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 1211
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:50:22
                            [post_date_gmt] => 2020-05-22 19:50:22
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 10:55:06
                            [post_modified_gmt] => 2021-06-22 10:55:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 1207
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:42:36
                            [post_date_gmt] => 2020-05-22 19:42:36
                            [post_content] => 
                            [post_title] => MPP License Agreement with Pfizer re Sutezolid
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 08:38:47
                            [post_modified_gmt] => 2021-07-07 08:38:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 1206
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:37:27
                            [post_date_gmt] => 2020-05-22 19:37:27
                            [post_content] => 
                            [post_title] => Gates Global Access Commitment & Humanitarian License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-global-access-commitment-and-humanitarian-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 14:17:10
                            [post_modified_gmt] => 2021-06-11 14:17:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 1200
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:35:05
                            [post_date_gmt] => 2020-05-22 19:35:05
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:30:10
                            [post_modified_gmt] => 2021-07-07 16:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 1205
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:33:17
                            [post_date_gmt] => 2020-05-22 19:33:17
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:22:22
                            [post_modified_gmt] => 2021-07-07 16:22:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 1204
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:31:46
                            [post_date_gmt] => 2020-05-22 19:31:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:23:03
                            [post_modified_gmt] => 2021-07-07 16:23:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 1203
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:30:52
                            [post_date_gmt] => 2020-05-22 19:30:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:21:41
                            [post_modified_gmt] => 2021-07-07 16:21:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 1202
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:28:49
                            [post_date_gmt] => 2020-05-22 19:28:49
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:27:22
                            [post_modified_gmt] => 2021-07-07 16:27:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 1201
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:26:29
                            [post_date_gmt] => 2020-05-22 19:26:29
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 16:29:47
                            [post_modified_gmt] => 2021-07-07 16:29:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 1199
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:21:57
                            [post_date_gmt] => 2020-05-22 19:21:57
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 08:35:03
                            [post_modified_gmt] => 2021-06-11 08:35:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 1198
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:12:54
                            [post_date_gmt] => 2020-05-22 19:12:54
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 08:23:10
                            [post_modified_gmt] => 2021-06-11 08:23:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 1190
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:59:48
                            [post_date_gmt] => 2020-05-22 01:59:48
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 13:58:32
                            [post_modified_gmt] => 2021-07-07 13:58:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 1187
                            [post_author] => 6
                            [post_date] => 2020-05-22 01:56:10
                            [post_date_gmt] => 2020-05-22 01:56:10
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 08:56:00
                            [post_modified_gmt] => 2021-06-01 08:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 1186
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:11:20
                            [post_date_gmt] => 2020-05-22 00:11:20
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 07:56:15
                            [post_modified_gmt] => 2021-06-09 07:56:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 1185
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:10:01
                            [post_date_gmt] => 2020-05-22 00:10:01
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 12:20:34
                            [post_modified_gmt] => 2021-06-17 12:20:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 1184
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:08:17
                            [post_date_gmt] => 2020-05-22 00:08:17
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-15 07:52:40
                            [post_modified_gmt] => 2021-06-15 07:52:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 1183
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:06:26
                            [post_date_gmt] => 2020-05-22 00:06:26
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 07:31:18
                            [post_modified_gmt] => 2021-06-11 07:31:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 1182
                            [post_author] => 6
                            [post_date] => 2020-05-22 00:02:42
                            [post_date_gmt] => 2020-05-22 00:02:42
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 07:52:45
                            [post_modified_gmt] => 2021-06-09 07:52:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 1178
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:55:50
                            [post_date_gmt] => 2020-05-21 23:55:50
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 09:31:51
                            [post_modified_gmt] => 2021-06-22 09:31:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 1177
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:53:56
                            [post_date_gmt] => 2020-05-21 23:53:56
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 13:50:50
                            [post_modified_gmt] => 2021-05-28 13:50:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 1176
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:52:12
                            [post_date_gmt] => 2020-05-21 23:52:12
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 14:16:14
                            [post_modified_gmt] => 2021-05-28 14:16:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 1175
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:44:57
                            [post_date_gmt] => 2020-05-21 23:44:57
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 14:26:08
                            [post_modified_gmt] => 2021-05-28 14:26:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 1173
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:37:42
                            [post_date_gmt] => 2020-05-21 23:37:42
                            [post_content] => 
                            [post_title] => CARB-X Research Subaward Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => carb-x-research-subaward-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 17:20:05
                            [post_modified_gmt] => 2021-06-01 17:20:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 1172
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:35:57
                            [post_date_gmt] => 2020-05-21 23:35:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 08:53:37
                            [post_modified_gmt] => 2021-06-22 08:53:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 1171
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:33:24
                            [post_date_gmt] => 2020-05-21 23:33:24
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 14:23:00
                            [post_modified_gmt] => 2021-06-17 14:23:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 1170
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:28:59
                            [post_date_gmt] => 2020-05-21 23:28:59
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:46:46
                            [post_modified_gmt] => 2020-08-06 07:46:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1170
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 1168
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:26:48
                            [post_date_gmt] => 2020-05-21 23:26:48
                            [post_content] => 
                            [post_title] => NIH Model License Agreement for Use by Non-Profit
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 14:57:13
                            [post_modified_gmt] => 2021-06-01 14:57:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1168
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 1166
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:26:07
                            [post_date_gmt] => 2020-05-21 23:26:07
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 13:50:07
                            [post_modified_gmt] => 2021-06-21 13:50:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1166
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 1165
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:23:57
                            [post_date_gmt] => 2020-05-21 23:23:57
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 10:04:00
                            [post_modified_gmt] => 2021-06-22 10:04:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1165
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 1164
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:22:37
                            [post_date_gmt] => 2020-05-21 23:22:37
                            [post_content] => 
                            [post_title] => AUTM Model Inter-Institutional Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => autm-model-iia
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 07:59:50
                            [post_modified_gmt] => 2021-06-09 07:59:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1164
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 1162
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:19:43
                            [post_date_gmt] => 2020-05-21 23:19:43
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:04:19
                            [post_modified_gmt] => 2021-07-21 11:04:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1162
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 1160
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:18:03
                            [post_date_gmt] => 2020-05-21 23:18:03
                            [post_content] => 
                            [post_title] => Aridis-PATH Vaccine Formulation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => aridis-path-vaccine-formulation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 07:41:09
                            [post_modified_gmt] => 2020-08-06 07:41:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1160
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 1159
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:14:15
                            [post_date_gmt] => 2020-05-21 23:14:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 12:46:56
                            [post_modified_gmt] => 2021-06-17 12:46:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 1158
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:12:13
                            [post_date_gmt] => 2020-05-21 23:12:13
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 08:37:38
                            [post_modified_gmt] => 2021-06-09 08:37:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 1156
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:10:39
                            [post_date_gmt] => 2020-05-21 23:10:39
                            [post_content] => 
                            [post_title] => WHO Standard Framework Memorandum of Understanding
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-standard-framework-memorandum-of-understanding
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 10:08:03
                            [post_modified_gmt] => 2021-06-01 10:08:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 1155
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:09:39
                            [post_date_gmt] => 2020-05-21 23:09:39
                            [post_content] => 
                            [post_title] => WHO Template Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => template-collaboration-agreement-with-who
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 10:29:16
                            [post_modified_gmt] => 2021-06-01 10:29:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 1150
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:53:25
                            [post_date_gmt] => 2020-05-21 22:53:25
                            [post_content] => 
                            [post_title] => Redacted Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => redacted-collaboration-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 15:03:20
                            [post_modified_gmt] => 2021-05-28 15:03:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 1147
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:50:33
                            [post_date_gmt] => 2020-05-21 22:50:33
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 14:32:11
                            [post_modified_gmt] => 2021-06-17 14:32:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 1145
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:48:08
                            [post_date_gmt] => 2020-05-21 22:48:08
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 13:25:04
                            [post_modified_gmt] => 2021-06-07 13:25:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1145
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 1143
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:46:30
                            [post_date_gmt] => 2020-05-21 22:46:30
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:18:12
                            [post_modified_gmt] => 2020-08-06 08:18:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 1141
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:43:46
                            [post_date_gmt] => 2020-05-21 22:43:46
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:19:21
                            [post_modified_gmt] => 2020-08-06 08:19:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 1140
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:37:27
                            [post_date_gmt] => 2020-05-21 22:37:27
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:04:31
                            [post_modified_gmt] => 2021-07-21 11:04:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 1139
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:35:04
                            [post_date_gmt] => 2020-05-21 22:35:04
                            [post_content] => 
                            [post_title] => Funder Development Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => funder-development-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 14:33:16
                            [post_modified_gmt] => 2021-05-28 14:33:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 1137
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:22:50
                            [post_date_gmt] => 2020-05-21 22:22:50
                            [post_content] => 
                            [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-16 07:27:54
                            [post_modified_gmt] => 2021-06-16 07:27:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 1135
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:19:46
                            [post_date_gmt] => 2020-05-21 22:19:46
                            [post_content] => 
                            [post_title] => NIH Model License Agreement for Use by Non-Profit
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-model-license-agreement-for-use-by-non-profit
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:25:31
                            [post_modified_gmt] => 2020-08-06 08:25:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 1134
                            [post_author] => 6
                            [post_date] => 2020-05-21 22:00:36
                            [post_date_gmt] => 2020-05-21 22:00:36
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:25:48
                            [post_modified_gmt] => 2020-08-06 08:25:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 1132
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:58:10
                            [post_date_gmt] => 2020-05-21 21:58:10
                            [post_content] => 
                            [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-joint-undertaking-model-consortium-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-21 14:49:45
                            [post_modified_gmt] => 2021-06-21 14:49:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1132
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 1128
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:50:04
                            [post_date_gmt] => 2020-05-21 21:50:04
                            [post_content] => 
                            [post_title] => IMI 2 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-2-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-22 10:34:13
                            [post_modified_gmt] => 2021-06-22 10:34:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 1127
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:47:49
                            [post_date_gmt] => 2020-05-21 21:47:49
                            [post_content] => 
                            [post_title] => BU Startup Exclusive License
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bu-startup-exclusive-license
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-06 08:08:46
                            [post_modified_gmt] => 2020-08-06 08:08:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 1125
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:44:59
                            [post_date_gmt] => 2020-05-21 21:44:59
                            [post_content] => 
                            [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 07:30:53
                            [post_modified_gmt] => 2021-06-11 07:30:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 1124
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:41:21
                            [post_date_gmt] => 2020-05-21 21:41:21
                            [post_content] => 
                            [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 17:34:59
                            [post_modified_gmt] => 2021-06-07 17:34:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1124
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 1123
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:37:52
                            [post_date_gmt] => 2020-05-21 21:37:52
                            [post_content] => 
                            [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 09:00:36
                            [post_modified_gmt] => 2021-06-09 09:00:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 1122
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:30:19
                            [post_date_gmt] => 2020-05-21 21:30:19
                            [post_content] => 
                            [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-07 12:47:37
                            [post_modified_gmt] => 2021-07-07 12:47:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 1120
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:28:37
                            [post_date_gmt] => 2020-05-21 21:28:37
                            [post_content] => 
                            [post_title] => AbbVie-MPP License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 07:29:48
                            [post_modified_gmt] => 2021-06-11 07:29:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 1118
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:24:00
                            [post_date_gmt] => 2020-05-21 21:24:00
                            [post_content] => 
                            [post_title] => MPP License Agreement with AbbVie (LPV r)
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-abbvie
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-10 13:22:55
                            [post_modified_gmt] => 2021-06-10 13:22:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 1117
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:17:31
                            [post_date_gmt] => 2020-05-21 21:17:31
                            [post_content] => 
                            [post_title] => MPP License Agreement with University of Liverpool
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpps-license-agreement-with-university-of-liverpool
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-11 07:52:12
                            [post_modified_gmt] => 2021-06-11 07:52:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 1114
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:13:15
                            [post_date_gmt] => 2020-05-21 21:13:15
                            [post_content] => 
                            [post_title] => MPP License Agreement with Gilead
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-license-agreement-with-gilead
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 11:14:37
                            [post_modified_gmt] => 2021-06-01 11:14:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 1113
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:09:47
                            [post_date_gmt] => 2020-05-21 21:09:47
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-05-28 13:57:38
                            [post_modified_gmt] => 2021-05-28 13:57:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 1112
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:06:05
                            [post_date_gmt] => 2020-05-21 21:06:05
                            [post_content] => 
                            [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-07-21 11:07:48
                            [post_modified_gmt] => 2021-07-21 11:07:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 1111
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:03:23
                            [post_date_gmt] => 2020-05-21 21:03:23
                            [post_content] => 
                            [post_title] => IMI 1 Model Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => imi-1-model-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-17 14:30:40
                            [post_modified_gmt] => 2021-06-17 14:30:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 1109
                            [post_author] => 6
                            [post_date] => 2020-05-21 21:01:18
                            [post_date_gmt] => 2020-05-21 21:01:18
                            [post_content] => 
                            [post_title] => CAVD Data & Materials Sharing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cavd-data-materials-sharing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2020-08-04 04:28:44
                            [post_modified_gmt] => 2020-08-04 04:28:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1109
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 1108
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:59:47
                            [post_date_gmt] => 2020-05-21 20:59:47
                            [post_content] => 
                            [post_title] => WHO Template Material Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => who-template-material-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-01 11:00:22
                            [post_modified_gmt] => 2021-06-01 11:00:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1108
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 1107
                            [post_author] => 6
                            [post_date] => 2020-05-21 20:57:25
                            [post_date_gmt] => 2020-05-21 20:57:25
                            [post_content] => 
                            [post_title] => Lambert Agreement D
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => lambert-agreement-d
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-07 14:53:31
                            [post_modified_gmt] => 2021-06-07 14:53:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1107
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 996
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:58:18
                            [post_date_gmt] => 2020-05-18 19:58:18
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-06-09 08:08:45
                            [post_modified_gmt] => 2021-06-09 08:08:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 344
            [current_post] => -1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 3436
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:48:49
                    [post_date_gmt] => 2021-07-01 03:48:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:01:08
                    [post_modified_gmt] => 2021-07-22 11:01:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 344
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 1c3df41be9f14460b814a5bb3f65f565
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [stopwords:WP_Query:private] => 
            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_agreement_q_rslts] => 
    [text_provision_q_rslts] => 
    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 3436
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:48:49
                    [post_date_gmt] => 2021-07-01 03:48:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:01:08
                    [post_modified_gmt] => 2021-07-22 11:01:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 3435
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:45:58
                    [post_date_gmt] => 2021-07-01 03:45:58
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:45:58
                    [post_modified_gmt] => 2021-07-01 03:45:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3435
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3434
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:44:18
                    [post_date_gmt] => 2021-07-01 03:44:18
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:44:18
                    [post_modified_gmt] => 2021-07-01 03:44:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3433
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:41:21
                    [post_date_gmt] => 2021-07-01 03:41:21
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:41:21
                    [post_modified_gmt] => 2021-07-01 03:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 3431
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:38:49
                    [post_date_gmt] => 2021-07-01 03:38:49
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:38:49
                    [post_modified_gmt] => 2021-07-01 03:38:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 3430
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:27:51
                    [post_date_gmt] => 2021-07-01 03:27:51
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 13:58:20
                    [post_modified_gmt] => 2021-07-22 13:58:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 3428
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:24:00
                    [post_date_gmt] => 2021-07-01 03:24:00
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:24:00
                    [post_modified_gmt] => 2021-07-01 03:24:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 3427
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:22:23
                    [post_date_gmt] => 2021-07-01 03:22:23
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:22:23
                    [post_modified_gmt] => 2021-07-01 03:22:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 3426
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:06:23
                    [post_date_gmt] => 2021-07-01 03:06:23
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:06:23
                    [post_modified_gmt] => 2021-07-01 03:06:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 3424
                    [post_author] => 6
                    [post_date] => 2021-07-01 03:03:57
                    [post_date_gmt] => 2021-07-01 03:03:57
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 03:03:57
                    [post_modified_gmt] => 2021-07-01 03:03:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 3422
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:58:21
                    [post_date_gmt] => 2021-07-01 02:58:21
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 15:32:57
                    [post_modified_gmt] => 2021-07-22 15:32:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 3421
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:56:30
                    [post_date_gmt] => 2021-07-01 02:56:30
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 02:56:30
                    [post_modified_gmt] => 2021-07-01 02:56:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 3420
                    [post_author] => 6
                    [post_date] => 2021-07-01 02:52:05
                    [post_date_gmt] => 2021-07-01 02:52:05
                    [post_content] => 
                    [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 02:52:05
                    [post_modified_gmt] => 2021-07-01 02:52:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 3418
                    [post_author] => 5
                    [post_date] => 2021-06-30 19:06:19
                    [post_date_gmt] => 2021-06-30 19:06:19
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 19:06:19
                    [post_modified_gmt] => 2021-06-30 19:06:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3418
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 3417
                    [post_author] => 5
                    [post_date] => 2021-06-30 19:04:34
                    [post_date_gmt] => 2021-06-30 19:04:34
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 19:04:34
                    [post_modified_gmt] => 2021-06-30 19:04:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3417
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 3416
                    [post_author] => 5
                    [post_date] => 2021-06-30 19:02:19
                    [post_date_gmt] => 2021-06-30 19:02:19
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 19:02:19
                    [post_modified_gmt] => 2021-06-30 19:02:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3416
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 3415
                    [post_author] => 5
                    [post_date] => 2021-06-30 19:00:20
                    [post_date_gmt] => 2021-06-30 19:00:20
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 19:00:20
                    [post_modified_gmt] => 2021-06-30 19:00:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3415
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 3414
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:54:43
                    [post_date_gmt] => 2021-06-30 18:54:43
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 12:51:17
                    [post_modified_gmt] => 2021-07-07 12:51:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3414
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 3413
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:52:08
                    [post_date_gmt] => 2021-06-30 18:52:08
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:52:08
                    [post_modified_gmt] => 2021-06-30 18:52:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3413
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 3412
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:48:13
                    [post_date_gmt] => 2021-06-30 18:48:13
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:48:13
                    [post_modified_gmt] => 2021-06-30 18:48:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3412
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 3411
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:39:53
                    [post_date_gmt] => 2021-06-30 18:39:53
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:39:53
                    [post_modified_gmt] => 2021-06-30 18:39:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3411
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 3410
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:37:02
                    [post_date_gmt] => 2021-06-30 18:37:02
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:44:47
                    [post_modified_gmt] => 2021-06-30 18:44:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3410
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 3409
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:34:04
                    [post_date_gmt] => 2021-06-30 18:34:04
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:34:04
                    [post_modified_gmt] => 2021-06-30 18:34:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3409
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 3407
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:29:55
                    [post_date_gmt] => 2021-06-30 18:29:55
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:29:55
                    [post_modified_gmt] => 2021-06-30 18:29:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3407
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 3406
                    [post_author] => 5
                    [post_date] => 2021-06-30 18:25:58
                    [post_date_gmt] => 2021-06-30 18:25:58
                    [post_content] => 
                    [post_title] => NIH-GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 18:26:40
                    [post_modified_gmt] => 2021-06-30 18:26:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 3379
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:56:54
                    [post_date_gmt] => 2021-06-30 17:56:54
                    [post_content] => 
                    [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 17:56:54
                    [post_modified_gmt] => 2021-06-30 17:56:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3379
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 3378
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:55:17
                    [post_date_gmt] => 2021-06-30 17:55:17
                    [post_content] => 
                    [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 17:55:17
                    [post_modified_gmt] => 2021-06-30 17:55:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3378
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 3377
                    [post_author] => 5
                    [post_date] => 2021-06-30 17:20:14
                    [post_date_gmt] => 2021-06-30 17:20:14
                    [post_content] => 
                    [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 17:20:14
                    [post_modified_gmt] => 2021-06-30 17:20:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3377
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 3376
                    [post_author] => 5
                    [post_date] => 2021-06-30 16:38:25
                    [post_date_gmt] => 2021-06-30 16:38:25
                    [post_content] => 
                    [post_title] => BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 16:38:25
                    [post_modified_gmt] => 2021-06-30 16:38:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3376
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 3375
                    [post_author] => 5
                    [post_date] => 2021-06-30 16:36:27
                    [post_date_gmt] => 2021-06-30 16:36:27
                    [post_content] => 
                    [post_title] => BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:06:55
                    [post_modified_gmt] => 2021-07-07 16:06:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3375
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 3369
                    [post_author] => 6
                    [post_date] => 2021-06-30 15:09:50
                    [post_date_gmt] => 2021-06-30 15:09:50
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:09:50
                    [post_modified_gmt] => 2021-06-30 15:09:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3369
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 3372
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:06:19
                    [post_date_gmt] => 2021-06-30 15:06:19
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:06:19
                    [post_modified_gmt] => 2021-06-30 15:06:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 3371
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:03:10
                    [post_date_gmt] => 2021-06-30 15:03:10
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:03:10
                    [post_modified_gmt] => 2021-06-30 15:03:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3371
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 3370
                    [post_author] => 5
                    [post_date] => 2021-06-30 15:01:06
                    [post_date_gmt] => 2021-06-30 15:01:06
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 15:01:06
                    [post_modified_gmt] => 2021-06-30 15:01:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 3368
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:58:39
                    [post_date_gmt] => 2021-06-30 14:58:39
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:58:39
                    [post_modified_gmt] => 2021-06-30 14:58:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 3367
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:55:06
                    [post_date_gmt] => 2021-06-30 14:55:06
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 10:37:50
                    [post_modified_gmt] => 2021-07-21 10:37:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3367
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 3366
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:53:53
                    [post_date_gmt] => 2021-06-30 14:53:53
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:53:53
                    [post_modified_gmt] => 2021-06-30 14:53:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 3365
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:51:27
                    [post_date_gmt] => 2021-06-30 14:51:27
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:51:27
                    [post_modified_gmt] => 2021-06-30 14:51:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3365
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 3364
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:47:34
                    [post_date_gmt] => 2021-06-30 14:47:34
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:47:34
                    [post_modified_gmt] => 2021-06-30 14:47:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 3362
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:47:24
                    [post_date_gmt] => 2021-06-30 14:47:24
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 13:52:40
                    [post_modified_gmt] => 2021-07-21 13:52:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3362
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 3363
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:45:00
                    [post_date_gmt] => 2021-06-30 14:45:00
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:45:00
                    [post_modified_gmt] => 2021-06-30 14:45:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3363
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 3359
                    [post_author] => 6
                    [post_date] => 2021-06-30 14:38:46
                    [post_date_gmt] => 2021-06-30 14:38:46
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 13:04:43
                    [post_modified_gmt] => 2021-07-22 13:04:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3359
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 3361
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:30:51
                    [post_date_gmt] => 2021-06-30 14:30:51
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:30:51
                    [post_modified_gmt] => 2021-06-30 14:30:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 3360
                    [post_author] => 5
                    [post_date] => 2021-06-30 14:28:40
                    [post_date_gmt] => 2021-06-30 14:28:40
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 14:28:40
                    [post_modified_gmt] => 2021-06-30 14:28:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 3356
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:53:23
                    [post_date_gmt] => 2021-06-30 13:53:23
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:53:23
                    [post_modified_gmt] => 2021-06-30 13:53:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 3358
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:47:23
                    [post_date_gmt] => 2021-06-30 13:47:23
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:47:23
                    [post_modified_gmt] => 2021-06-30 13:47:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3358
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 3357
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:41:11
                    [post_date_gmt] => 2021-06-30 13:41:11
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 13:20:28
                    [post_modified_gmt] => 2021-07-01 13:20:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3357
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 3355
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:30:36
                    [post_date_gmt] => 2021-06-30 13:30:36
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 13:21:49
                    [post_modified_gmt] => 2021-07-01 13:21:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3355
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 3354
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:29:21
                    [post_date_gmt] => 2021-06-30 13:29:21
                    [post_content] => 
                    [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:29:21
                    [post_modified_gmt] => 2021-06-30 13:29:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 3353
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:25:17
                    [post_date_gmt] => 2021-06-30 13:25:17
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:25:17
                    [post_modified_gmt] => 2021-06-30 13:25:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3353
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 3352
                    [post_author] => 5
                    [post_date] => 2021-06-30 13:24:49
                    [post_date_gmt] => 2021-06-30 13:24:49
                    [post_content] => 
                    [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:24:49
                    [post_modified_gmt] => 2021-06-30 13:24:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 3350
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:18:18
                    [post_date_gmt] => 2021-06-30 13:18:18
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:18:18
                    [post_modified_gmt] => 2021-06-30 13:18:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3350
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 3347
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:12:31
                    [post_date_gmt] => 2021-06-30 13:12:31
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:14:40
                    [post_modified_gmt] => 2021-06-30 13:14:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3347
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 3346
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:07:59
                    [post_date_gmt] => 2021-06-30 13:07:59
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:07:59
                    [post_modified_gmt] => 2021-06-30 13:07:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3346
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 3345
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:04:52
                    [post_date_gmt] => 2021-06-30 13:04:52
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 13:19:28
                    [post_modified_gmt] => 2021-07-01 13:19:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3345
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 3344
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:02:36
                    [post_date_gmt] => 2021-06-30 13:02:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 13:03:45
                    [post_modified_gmt] => 2021-06-30 13:03:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 3343
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:57:07
                    [post_date_gmt] => 2021-06-30 12:57:07
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-21
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:57:07
                    [post_modified_gmt] => 2021-06-30 12:57:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 3342
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:50:17
                    [post_date_gmt] => 2021-06-30 12:50:17
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 10:15:57
                    [post_modified_gmt] => 2021-07-22 10:15:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 3341
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:44:43
                    [post_date_gmt] => 2021-06-30 12:44:43
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:44:43
                    [post_modified_gmt] => 2021-06-30 12:44:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 3340
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:39:34
                    [post_date_gmt] => 2021-06-30 12:39:34
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:39:34
                    [post_modified_gmt] => 2021-06-30 12:39:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3340
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 3339
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:37:28
                    [post_date_gmt] => 2021-06-30 12:37:28
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:37:28
                    [post_modified_gmt] => 2021-06-30 12:37:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 3338
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:27:08
                    [post_date_gmt] => 2021-06-30 12:27:08
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:32:08
                    [post_modified_gmt] => 2021-06-30 12:32:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 3337
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:21:58
                    [post_date_gmt] => 2021-06-30 12:21:58
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:22:26
                    [post_modified_gmt] => 2021-06-30 12:22:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3337
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 3335
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:20:18
                    [post_date_gmt] => 2021-06-30 12:20:18
                    [post_content] => 
                    [post_title] => BMGF – CureVac, Global Access Commitments Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bmgf-curevac-global-access-commitments-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-01 13:17:56
                    [post_modified_gmt] => 2021-07-01 13:17:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3335
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 3336
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:18:57
                    [post_date_gmt] => 2021-06-30 12:18:57
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:18:57
                    [post_modified_gmt] => 2021-06-30 12:18:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 3331
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:09:31
                    [post_date_gmt] => 2021-06-30 12:09:31
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:16:00
                    [post_modified_gmt] => 2021-06-30 12:16:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 3330
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:06:21
                    [post_date_gmt] => 2021-06-30 12:06:21
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 12:06:21
                    [post_modified_gmt] => 2021-06-30 12:06:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3330
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 3329
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:04:02
                    [post_date_gmt] => 2021-06-30 12:04:02
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-06 13:46:56
                    [post_modified_gmt] => 2021-07-06 13:46:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 3327
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:47:34
                    [post_date_gmt] => 2021-06-30 11:47:34
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-06 12:43:11
                    [post_modified_gmt] => 2021-07-06 12:43:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 3326
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:35:26
                    [post_date_gmt] => 2021-06-30 11:35:26
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 11:36:06
                    [post_modified_gmt] => 2021-06-30 11:36:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 3325
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:31:20
                    [post_date_gmt] => 2021-06-30 11:31:20
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 11:31:20
                    [post_modified_gmt] => 2021-06-30 11:31:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3325
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 3323
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:15:16
                    [post_date_gmt] => 2021-06-30 11:15:16
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 11:19:00
                    [post_modified_gmt] => 2021-06-30 11:19:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 3321
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:12:36
                    [post_date_gmt] => 2021-06-30 11:12:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 13-commercial-benefits-arising-from-commercial-use-13-3-use-of-product-in-affected-territory-only-cepi-intends-to-take-reasonable-efforts-to-ensure-that-the-products-will-be-utilized-in-the-affected
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 11:13:04
                    [post_modified_gmt] => 2021-06-30 11:13:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 3319
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:02:41
                    [post_date_gmt] => 2021-06-30 11:02:41
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 12:28:51
                    [post_modified_gmt] => 2021-07-07 12:28:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3319
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 3318
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:46:25
                    [post_date_gmt] => 2021-06-30 10:46:25
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:46:25
                    [post_modified_gmt] => 2021-06-30 10:46:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 3317
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:29:34
                    [post_date_gmt] => 2021-06-30 10:29:34
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:29:34
                    [post_modified_gmt] => 2021-06-30 10:29:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3317
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 3316
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:25:45
                    [post_date_gmt] => 2021-06-30 10:25:45
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-06 13:50:34
                    [post_modified_gmt] => 2021-07-06 13:50:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 3315
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:19:01
                    [post_date_gmt] => 2021-06-30 10:19:01
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:19:01
                    [post_modified_gmt] => 2021-06-30 10:19:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 3312
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:06:34
                    [post_date_gmt] => 2021-06-30 10:06:34
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:06:34
                    [post_modified_gmt] => 2021-06-30 10:06:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3312
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 3311
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:04:32
                    [post_date_gmt] => 2021-06-30 10:04:32
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:04:32
                    [post_modified_gmt] => 2021-06-30 10:04:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3311
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 3310
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:01:40
                    [post_date_gmt] => 2021-06-30 10:01:40
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 10:01:40
                    [post_modified_gmt] => 2021-06-30 10:01:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3310
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 3309
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:51:28
                    [post_date_gmt] => 2021-06-30 09:51:28
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:51:28
                    [post_modified_gmt] => 2021-06-30 09:51:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3309
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 3308
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:48:24
                    [post_date_gmt] => 2021-06-30 09:48:24
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:48:24
                    [post_modified_gmt] => 2021-06-30 09:48:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3308
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 3307
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:44:19
                    [post_date_gmt] => 2021-06-30 09:44:19
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:45:07
                    [post_modified_gmt] => 2021-06-30 09:45:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3307
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 3305
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:35:10
                    [post_date_gmt] => 2021-06-30 09:35:10
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-06 11:48:57
                    [post_modified_gmt] => 2021-07-06 11:48:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3305
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 3304
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:30:56
                    [post_date_gmt] => 2021-06-30 09:30:56
                    [post_content] => 
                    [post_title] => UK Government – Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:30:56
                    [post_modified_gmt] => 2021-06-30 09:30:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3304
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 3303
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:26:40
                    [post_date_gmt] => 2021-06-30 09:26:40
                    [post_content] => 
                    [post_title] => UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:26:40
                    [post_modified_gmt] => 2021-06-30 09:26:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3303
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 3302
                    [post_author] => 6
                    [post_date] => 2021-06-30 09:21:45
                    [post_date_gmt] => 2021-06-30 09:21:45
                    [post_content] => 
                    [post_title] => UK Government - Roche, REGN-COV2 Supply Agreement for Pandemic Purposes
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 3302
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-30 09:26:51
                    [post_modified_gmt] => 2021-06-30 09:26:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3302
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 3221
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:23:49
                    [post_date_gmt] => 2021-06-28 12:23:49
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:23:49
                    [post_modified_gmt] => 2021-06-28 12:23:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 3220
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:22:09
                    [post_date_gmt] => 2021-06-28 12:22:09
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:22:09
                    [post_modified_gmt] => 2021-06-28 12:22:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 3219
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:19:29
                    [post_date_gmt] => 2021-06-28 12:19:29
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:19:29
                    [post_modified_gmt] => 2021-06-28 12:19:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 3218
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:16:20
                    [post_date_gmt] => 2021-06-28 12:16:20
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:16:20
                    [post_modified_gmt] => 2021-06-28 12:16:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 3217
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:14:37
                    [post_date_gmt] => 2021-06-28 12:14:37
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:14:37
                    [post_modified_gmt] => 2021-06-28 12:14:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 3216
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:11:22
                    [post_date_gmt] => 2021-06-28 12:11:22
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:11:22
                    [post_modified_gmt] => 2021-06-28 12:11:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 3215
                    [post_author] => 6
                    [post_date] => 2021-06-28 12:07:55
                    [post_date_gmt] => 2021-06-28 12:07:55
                    [post_content] => 
                    [post_title] => Pfizer – Peru, COVID-19 Vaccine Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-28 12:07:55
                    [post_modified_gmt] => 2021-06-28 12:07:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 3211
                    [post_author] => 5
                    [post_date] => 2021-06-22 08:43:07
                    [post_date_gmt] => 2021-06-22 08:43:07
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:43:07
                    [post_modified_gmt] => 2021-06-22 08:43:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3211
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 3127
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:08:41
                    [post_date_gmt] => 2021-06-03 15:08:41
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:02
                    [post_modified_gmt] => 2021-06-04 08:01:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 3126
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:05:40
                    [post_date_gmt] => 2021-06-03 15:05:40
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:29
                    [post_modified_gmt] => 2021-06-04 08:01:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 3125
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:03:17
                    [post_date_gmt] => 2021-06-03 15:03:17
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:01:54
                    [post_modified_gmt] => 2021-06-04 08:01:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 3124
                    [post_author] => 6
                    [post_date] => 2021-06-03 15:01:23
                    [post_date_gmt] => 2021-06-03 15:01:23
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:02:32
                    [post_modified_gmt] => 2021-06-04 08:02:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3124
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 3123
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:51:22
                    [post_date_gmt] => 2021-06-03 14:51:22
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 12:37:50
                    [post_modified_gmt] => 2021-07-21 12:37:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 3122
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:45:44
                    [post_date_gmt] => 2021-06-03 14:45:44
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:05:37
                    [post_modified_gmt] => 2021-06-04 08:05:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 3121
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:26:32
                    [post_date_gmt] => 2021-06-03 14:26:32
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:09:56
                    [post_modified_gmt] => 2021-06-04 08:09:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 3120
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:24:03
                    [post_date_gmt] => 2021-06-03 14:24:03
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 08:13:26
                    [post_modified_gmt] => 2021-06-04 08:13:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 3119
                    [post_author] => 6
                    [post_date] => 2021-06-03 14:21:50
                    [post_date_gmt] => 2021-06-03 14:21:50
                    [post_content] => 
                    [post_title] => Pfizer/BioNTech-Dominican Republic Binding Term Sheet
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 13:54:22
                    [post_modified_gmt] => 2021-06-07 13:54:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 2972
                    [post_author] => 5
                    [post_date] => 2021-06-01 10:17:19
                    [post_date_gmt] => 2021-06-01 10:17:19
                    [post_content] => 
                    [post_title] => WHO Template Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-collaboration-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 10:17:19
                    [post_modified_gmt] => 2021-06-01 10:17:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2972
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 2956
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:56:15
                    [post_date_gmt] => 2021-05-28 18:56:15
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:49:49
                    [post_modified_gmt] => 2021-06-02 08:49:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2956
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 2961
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:55:47
                    [post_date_gmt] => 2021-05-28 18:55:47
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:23:30
                    [post_modified_gmt] => 2021-06-02 09:23:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2961
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 2965
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:55:12
                    [post_date_gmt] => 2021-05-28 18:55:12
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 13:00:56
                    [post_modified_gmt] => 2021-06-08 13:00:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2965
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 2947
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:54:17
                    [post_date_gmt] => 2021-05-28 18:54:17
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:16:41
                    [post_modified_gmt] => 2021-06-02 08:16:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 2960
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:53:36
                    [post_date_gmt] => 2021-05-28 18:53:36
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:21:06
                    [post_modified_gmt] => 2021-06-02 09:21:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2960
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 2964
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:53:11
                    [post_date_gmt] => 2021-05-28 18:53:11
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:02:13
                    [post_modified_gmt] => 2021-06-02 08:02:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2964
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 2958
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:52:54
                    [post_date_gmt] => 2021-05-28 18:52:54
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:14:15
                    [post_modified_gmt] => 2021-06-02 09:14:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2958
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 2949
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:52:06
                    [post_date_gmt] => 2021-05-28 18:52:06
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-23 13:13:35
                    [post_modified_gmt] => 2021-06-23 13:13:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2949
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 2957
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:51:39
                    [post_date_gmt] => 2021-05-28 18:51:39
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:09:58
                    [post_modified_gmt] => 2021-06-02 09:09:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2957
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 2962
                    [post_author] => 6
                    [post_date] => 2021-05-28 18:50:18
                    [post_date_gmt] => 2021-05-28 18:50:18
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 09:19:22
                    [post_modified_gmt] => 2021-06-02 09:19:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 2945
                    [post_author] => 6
                    [post_date] => 2021-05-28 14:03:27
                    [post_date_gmt] => 2021-05-28 14:03:27
                    [post_content] => 
                    [post_title] => AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 08:51:28
                    [post_modified_gmt] => 2021-06-02 08:51:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2945
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-16 15:39:30
                    [post_modified_gmt] => 2021-06-16 15:39:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 2908
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:08:05
                    [post_date_gmt] => 2021-05-19 15:08:05
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 12:18:00
                    [post_modified_gmt] => 2021-07-21 12:18:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:46:20
                    [post_date_gmt] => 2021-05-19 14:46:20
                    [post_content] => 
                    [post_title] => Novavax – CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 14:10:32
                    [post_modified_gmt] => 2021-07-22 14:10:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 2893
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:40:45
                    [post_date_gmt] => 2021-05-19 14:40:45
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 08:56:01
                    [post_modified_gmt] => 2021-06-21 08:56:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 2892
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:30:23
                    [post_date_gmt] => 2021-05-14 19:30:23
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 15:13:39
                    [post_modified_gmt] => 2021-06-02 15:13:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 2890
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:14:07
                    [post_date_gmt] => 2021-05-14 19:14:07
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 12:49:25
                    [post_modified_gmt] => 2021-06-08 12:49:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 2889
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:09:07
                    [post_date_gmt] => 2021-05-14 19:09:07
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 19:09:07
                    [post_modified_gmt] => 2021-05-14 19:09:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 2888
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:01:08
                    [post_date_gmt] => 2021-05-14 19:01:08
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-20 12:23:46
                    [post_modified_gmt] => 2021-05-20 12:23:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2888
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 2886
                    [post_author] => 6
                    [post_date] => 2021-05-14 18:21:24
                    [post_date_gmt] => 2021-05-14 18:21:24
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 18:21:24
                    [post_modified_gmt] => 2021-05-14 18:21:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2886
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 2885
                    [post_author] => 5
                    [post_date] => 2021-05-14 18:17:37
                    [post_date_gmt] => 2021-05-14 18:17:37
                    [post_content] => 
                    [post_title] => Novavax– CEPI Outbreak Response to Novel Coronavirus (COVID-19) Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 18:17:37
                    [post_modified_gmt] => 2021-05-14 18:17:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 2873
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:17:08
                    [post_date_gmt] => 2021-05-11 15:17:08
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-26 08:35:05
                    [post_modified_gmt] => 2021-05-26 08:35:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 2872
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:14:24
                    [post_date_gmt] => 2021-05-11 15:14:24
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 14:35:52
                    [post_modified_gmt] => 2021-06-07 14:35:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 2870
                    [post_author] => 6
                    [post_date] => 2021-05-11 15:07:59
                    [post_date_gmt] => 2021-05-11 15:07:59
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-15 09:15:21
                    [post_modified_gmt] => 2021-06-15 09:15:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 2869
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:53:04
                    [post_date_gmt] => 2021-05-11 14:53:04
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:15:00
                    [post_modified_gmt] => 2021-05-14 09:15:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 2868
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:44:06
                    [post_date_gmt] => 2021-05-11 14:44:06
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:26:33
                    [post_modified_gmt] => 2021-05-14 09:26:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2868
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 2867
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:28:02
                    [post_date_gmt] => 2021-05-11 14:28:02
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2867
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:21:28
                    [post_modified_gmt] => 2021-06-01 09:21:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 2865
                    [post_author] => 6
                    [post_date] => 2021-05-11 14:25:05
                    [post_date_gmt] => 2021-05-11 14:25:05
                    [post_content] => 
                    [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-14 09:48:01
                    [post_modified_gmt] => 2021-05-14 09:48:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2865
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 2824
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:39:49
                    [post_date_gmt] => 2021-04-16 16:39:49
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:39:49
                    [post_modified_gmt] => 2021-04-16 16:39:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 2823
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:17:11
                    [post_date_gmt] => 2021-04-16 16:17:11
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:17:11
                    [post_modified_gmt] => 2021-04-16 16:17:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2823
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 2822
                    [post_author] => 5
                    [post_date] => 2021-04-16 16:09:31
                    [post_date_gmt] => 2021-04-16 16:09:31
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 16:09:31
                    [post_modified_gmt] => 2021-04-16 16:09:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 2821
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:55:04
                    [post_date_gmt] => 2021-04-16 12:55:04
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:55:04
                    [post_modified_gmt] => 2021-04-16 12:55:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2821
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 2820
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:44:14
                    [post_date_gmt] => 2021-04-16 12:44:14
                    [post_content] => 
                    [post_title] => Regeneron – ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 11:55:37
                    [post_modified_gmt] => 2021-05-28 11:55:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 2819
                    [post_author] => 5
                    [post_date] => 2021-04-16 12:12:32
                    [post_date_gmt] => 2021-04-16 12:12:32
                    [post_content] => 
                    [post_title] => Regeneron - ATI Agreement for Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-04-16 12:15:57
                    [post_modified_gmt] => 2021-04-16 12:15:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2819
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 2744
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:12:35
                    [post_date_gmt] => 2021-03-30 15:12:35
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:21
                    [post_modified_gmt] => 2021-05-17 13:21:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [141] => WP_Post Object
                (
                    [ID] => 2749
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:10:16
                    [post_date_gmt] => 2021-03-30 15:10:16
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:43:25
                    [post_modified_gmt] => 2021-06-01 09:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [142] => WP_Post Object
                (
                    [ID] => 2748
                    [post_author] => 5
                    [post_date] => 2021-03-30 15:05:46
                    [post_date_gmt] => 2021-03-30 15:05:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 2748
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:40
                    [post_modified_gmt] => 2021-05-17 13:21:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [143] => WP_Post Object
                (
                    [ID] => 2740
                    [post_author] => 5
                    [post_date] => 2021-03-30 14:54:54
                    [post_date_gmt] => 2021-03-30 14:54:54
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:21:50
                    [post_modified_gmt] => 2021-05-17 13:21:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2740
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [144] => WP_Post Object
                (
                    [ID] => 2743
                    [post_author] => 5
                    [post_date] => 2021-03-24 15:11:40
                    [post_date_gmt] => 2021-03-24 15:11:40
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:13
                    [post_modified_gmt] => 2021-05-17 13:22:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [145] => WP_Post Object
                (
                    [ID] => 2742
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:37:07
                    [post_date_gmt] => 2021-03-24 13:37:07
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 14:14:47
                    [post_modified_gmt] => 2021-07-22 14:14:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [146] => WP_Post Object
                (
                    [ID] => 2741
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:32:55
                    [post_date_gmt] => 2021-03-24 13:32:55
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:24
                    [post_modified_gmt] => 2021-05-17 13:22:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [147] => WP_Post Object
                (
                    [ID] => 2739
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:12:14
                    [post_date_gmt] => 2021-03-24 13:12:14
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:22:33
                    [post_modified_gmt] => 2021-05-17 13:22:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [148] => WP_Post Object
                (
                    [ID] => 2738
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:04:24
                    [post_date_gmt] => 2021-03-24 13:04:24
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:03:59
                    [post_modified_gmt] => 2021-06-09 09:03:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2738
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [149] => WP_Post Object
                (
                    [ID] => 2737
                    [post_author] => 5
                    [post_date] => 2021-03-24 13:00:46
                    [post_date_gmt] => 2021-03-24 13:00:46
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:04
                    [post_modified_gmt] => 2021-05-17 13:23:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [150] => WP_Post Object
                (
                    [ID] => 2736
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:15:15
                    [post_date_gmt] => 2021-03-23 18:15:15
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:17
                    [post_modified_gmt] => 2021-05-17 13:23:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [151] => WP_Post Object
                (
                    [ID] => 2735
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:05:28
                    [post_date_gmt] => 2021-03-23 18:05:28
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:23:28
                    [post_modified_gmt] => 2021-05-17 13:23:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2735
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [152] => WP_Post Object
                (
                    [ID] => 2734
                    [post_author] => 5
                    [post_date] => 2021-03-23 18:01:22
                    [post_date_gmt] => 2021-03-23 18:01:22
                    [post_content] => 
                    [post_title] => Novavax – US Army Agreement for Research & Development of COVID-19 Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 17:12:58
                    [post_modified_gmt] => 2021-06-07 17:12:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [153] => WP_Post Object
                (
                    [ID] => 2543
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:15:58
                    [post_date_gmt] => 2021-03-12 18:15:58
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:24:40
                    [post_modified_gmt] => 2021-05-17 13:24:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [154] => WP_Post Object
                (
                    [ID] => 2540
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:12:48
                    [post_date_gmt] => 2021-03-12 18:12:48
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 13:52:44
                    [post_modified_gmt] => 2021-07-07 13:52:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [155] => WP_Post Object
                (
                    [ID] => 2541
                    [post_author] => 5
                    [post_date] => 2021-03-12 18:11:14
                    [post_date_gmt] => 2021-03-12 18:11:14
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 16:06:34
                    [post_modified_gmt] => 2021-05-28 16:06:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [156] => WP_Post Object
                (
                    [ID] => 2542
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:21:07
                    [post_date_gmt] => 2021-03-12 14:21:07
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 15:59:01
                    [post_modified_gmt] => 2021-05-28 15:59:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [157] => WP_Post Object
                (
                    [ID] => 2544
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:16:06
                    [post_date_gmt] => 2021-03-12 14:16:06
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:14
                    [post_modified_gmt] => 2021-05-17 13:25:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [158] => WP_Post Object
                (
                    [ID] => 2545
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:14:38
                    [post_date_gmt] => 2021-03-12 14:14:38
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:23
                    [post_modified_gmt] => 2021-05-17 13:25:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [159] => WP_Post Object
                (
                    [ID] => 2546
                    [post_author] => 5
                    [post_date] => 2021-03-12 14:13:16
                    [post_date_gmt] => 2021-03-12 14:13:16
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:35
                    [post_modified_gmt] => 2021-05-17 13:25:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2546
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [160] => WP_Post Object
                (
                    [ID] => 2547
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:58:55
                    [post_date_gmt] => 2021-03-12 13:58:55
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 10:39:30
                    [post_modified_gmt] => 2021-07-21 10:39:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [161] => WP_Post Object
                (
                    [ID] => 2548
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:55:59
                    [post_date_gmt] => 2021-03-12 13:55:59
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-04 09:42:06
                    [post_modified_gmt] => 2021-06-04 09:42:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2548
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [162] => WP_Post Object
                (
                    [ID] => 2549
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:50:41
                    [post_date_gmt] => 2021-03-12 13:50:41
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:25:58
                    [post_modified_gmt] => 2021-05-17 13:25:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [163] => WP_Post Object
                (
                    [ID] => 2553
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:47:42
                    [post_date_gmt] => 2021-03-12 13:47:42
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 16:09:05
                    [post_modified_gmt] => 2021-05-28 16:09:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [164] => WP_Post Object
                (
                    [ID] => 2554
                    [post_author] => 5
                    [post_date] => 2021-03-12 13:44:47
                    [post_date_gmt] => 2021-03-12 13:44:47
                    [post_content] => 
                    [post_title] => AstraZeneca - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:26:22
                    [post_modified_gmt] => 2021-05-17 13:26:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2554
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [165] => WP_Post Object
                (
                    [ID] => 2457
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:57
                    [post_date_gmt] => 2021-02-25 15:25:57
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:09:35
                    [post_modified_gmt] => 2021-05-17 13:09:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [166] => WP_Post Object
                (
                    [ID] => 2459
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:25:31
                    [post_date_gmt] => 2021-02-25 15:25:31
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:50:06
                    [post_modified_gmt] => 2021-06-01 09:50:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2459
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [167] => WP_Post Object
                (
                    [ID] => 2460
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:51
                    [post_date_gmt] => 2021-02-25 15:23:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:51
                    [post_modified_gmt] => 2021-02-25 15:23:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2460
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [168] => WP_Post Object
                (
                    [ID] => 2461
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:35
                    [post_date_gmt] => 2021-02-25 15:23:35
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:35
                    [post_modified_gmt] => 2021-02-25 15:23:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [169] => WP_Post Object
                (
                    [ID] => 2462
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:23:19
                    [post_date_gmt] => 2021-02-25 15:23:19
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:23:19
                    [post_modified_gmt] => 2021-02-25 15:23:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [170] => WP_Post Object
                (
                    [ID] => 2463
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:22:52
                    [post_date_gmt] => 2021-02-25 15:22:52
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:55:43
                    [post_modified_gmt] => 2021-06-01 09:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [171] => WP_Post Object
                (
                    [ID] => 2464
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:51
                    [post_date_gmt] => 2021-02-25 15:21:51
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:21:51
                    [post_modified_gmt] => 2021-02-25 15:21:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [172] => WP_Post Object
                (
                    [ID] => 2465
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:21:32
                    [post_date_gmt] => 2021-02-25 15:21:32
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 10:25:45
                    [post_modified_gmt] => 2021-05-27 10:25:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [173] => WP_Post Object
                (
                    [ID] => 2466
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:40
                    [post_date_gmt] => 2021-02-25 15:20:40
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 14:59:57
                    [post_modified_gmt] => 2021-06-21 14:59:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [174] => WP_Post Object
                (
                    [ID] => 2467
                    [post_author] => 5
                    [post_date] => 2021-02-25 15:20:15
                    [post_date_gmt] => 2021-02-25 15:20:15
                    [post_content] => 
                    [post_title] => Sanofi – DoD Agreement for Adjuvanted Recombinant COVID-19 Vaccine Development
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-02-25 15:20:15
                    [post_modified_gmt] => 2021-02-25 15:20:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [175] => WP_Post Object
                (
                    [ID] => 2470
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:24:13
                    [post_date_gmt] => 2021-01-25 13:24:13
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:26:57
                    [post_modified_gmt] => 2021-05-17 13:26:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [176] => WP_Post Object
                (
                    [ID] => 2472
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:23:03
                    [post_date_gmt] => 2021-01-25 13:23:03
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:05
                    [post_modified_gmt] => 2021-05-17 13:27:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2472
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [177] => WP_Post Object
                (
                    [ID] => 2473
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:21:58
                    [post_date_gmt] => 2021-01-25 13:21:58
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:13
                    [post_modified_gmt] => 2021-05-17 13:27:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [178] => WP_Post Object
                (
                    [ID] => 2474
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:19:34
                    [post_date_gmt] => 2021-01-25 13:19:34
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 11:53:52
                    [post_modified_gmt] => 2021-07-22 11:53:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [179] => WP_Post Object
                (
                    [ID] => 2475
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:53
                    [post_date_gmt] => 2021-01-25 13:18:53
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:28
                    [post_modified_gmt] => 2021-05-17 13:27:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [180] => WP_Post Object
                (
                    [ID] => 2476
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:18:09
                    [post_date_gmt] => 2021-01-25 13:18:09
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:36
                    [post_modified_gmt] => 2021-05-17 13:27:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [181] => WP_Post Object
                (
                    [ID] => 2477
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:16:23
                    [post_date_gmt] => 2021-01-25 13:16:23
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:27:44
                    [post_modified_gmt] => 2021-05-17 13:27:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [182] => WP_Post Object
                (
                    [ID] => 2478
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:14:33
                    [post_date_gmt] => 2021-01-25 13:14:33
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 11:31:53
                    [post_modified_gmt] => 2021-06-17 11:31:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2478
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [183] => WP_Post Object
                (
                    [ID] => 2479
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:12:32
                    [post_date_gmt] => 2021-01-25 13:12:32
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 17:33:15
                    [post_modified_gmt] => 2021-06-01 17:33:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [184] => WP_Post Object
                (
                    [ID] => 2480
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:47
                    [post_date_gmt] => 2021-01-25 13:11:47
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:28:03
                    [post_modified_gmt] => 2021-05-17 13:28:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [185] => WP_Post Object
                (
                    [ID] => 2481
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:11:08
                    [post_date_gmt] => 2021-01-25 13:11:08
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 09:53:25
                    [post_modified_gmt] => 2021-06-17 09:53:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [186] => WP_Post Object
                (
                    [ID] => 2482
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:09:37
                    [post_date_gmt] => 2021-01-25 13:09:37
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-16 15:58:24
                    [post_modified_gmt] => 2021-06-16 15:58:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [187] => WP_Post Object
                (
                    [ID] => 2483
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:51
                    [post_date_gmt] => 2021-01-25 13:08:51
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-17 13:28:30
                    [post_modified_gmt] => 2021-05-17 13:28:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2483
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [188] => WP_Post Object
                (
                    [ID] => 2471
                    [post_author] => 5
                    [post_date] => 2021-01-25 13:08:02
                    [post_date_gmt] => 2021-01-25 13:08:02
                    [post_content] => 
                    [post_title] => CureVac - European Commission COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-10 10:15:54
                    [post_modified_gmt] => 2021-06-10 10:15:54
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [189] => WP_Post Object
                (
                    [ID] => 2454
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:44:16
                    [post_date_gmt] => 2021-01-19 11:44:16
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:43:04
                    [post_modified_gmt] => 2021-05-27 09:43:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2454
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [190] => WP_Post Object
                (
                    [ID] => 2452
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:41:19
                    [post_date_gmt] => 2021-01-19 11:41:19
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-02 12:14:43
                    [post_modified_gmt] => 2021-06-02 12:14:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [191] => WP_Post Object
                (
                    [ID] => 2450
                    [post_author] => 5
                    [post_date] => 2021-01-19 11:04:23
                    [post_date_gmt] => 2021-01-19 11:04:23
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:47:15
                    [post_modified_gmt] => 2021-05-27 09:47:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [192] => WP_Post Object
                (
                    [ID] => 2449
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:47:27
                    [post_date_gmt] => 2021-01-19 10:47:27
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:47:52
                    [post_modified_gmt] => 2021-05-27 09:47:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [193] => WP_Post Object
                (
                    [ID] => 2448
                    [post_author] => 5
                    [post_date] => 2021-01-19 10:24:45
                    [post_date_gmt] => 2021-01-19 10:24:45
                    [post_content] => 
                    [post_title] => Moderna – DoD Supply Agreement for mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:49:00
                    [post_modified_gmt] => 2021-05-27 09:49:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [194] => WP_Post Object
                (
                    [ID] => 2445
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:31:14
                    [post_date_gmt] => 2021-01-19 09:31:14
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 08:28:27
                    [post_modified_gmt] => 2021-07-07 08:28:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2445
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [195] => WP_Post Object
                (
                    [ID] => 2444
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:27:20
                    [post_date_gmt] => 2021-01-19 09:27:20
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:33:58
                    [post_modified_gmt] => 2021-05-27 09:33:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [196] => WP_Post Object
                (
                    [ID] => 2443
                    [post_author] => 5
                    [post_date] => 2021-01-19 09:14:03
                    [post_date_gmt] => 2021-01-19 09:14:03
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:34:37
                    [post_modified_gmt] => 2021-05-27 09:34:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [197] => WP_Post Object
                (
                    [ID] => 2442
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:56:32
                    [post_date_gmt] => 2021-01-19 06:56:32
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 08:30:33
                    [post_modified_gmt] => 2021-07-07 08:30:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [198] => WP_Post Object
                (
                    [ID] => 2441
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:48:04
                    [post_date_gmt] => 2021-01-19 06:48:04
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:36:53
                    [post_modified_gmt] => 2021-05-27 09:36:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [199] => WP_Post Object
                (
                    [ID] => 2440
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:45:33
                    [post_date_gmt] => 2021-01-19 06:45:33
                    [post_content] => 
                    [post_title] => Moderna – BARDA Contract for Development of mRNA Vaccine
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-27 09:37:25
                    [post_modified_gmt] => 2021-05-27 09:37:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2440
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [200] => WP_Post Object
                (
                    [ID] => 2425
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:33
                    [post_date_gmt] => 2020-12-14 15:02:33
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-01-22 12:13:42
                    [post_modified_gmt] => 2021-01-22 12:13:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2425
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [201] => WP_Post Object
                (
                    [ID] => 2426
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:02:08
                    [post_date_gmt] => 2020-12-14 15:02:08
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 18:47:49
                    [post_modified_gmt] => 2021-06-01 18:47:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [202] => WP_Post Object
                (
                    [ID] => 2424
                    [post_author] => 5
                    [post_date] => 2020-12-14 15:01:40
                    [post_date_gmt] => 2020-12-14 15:01:40
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 08:18:09
                    [post_modified_gmt] => 2021-06-09 08:18:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [203] => WP_Post Object
                (
                    [ID] => 2422
                    [post_author] => 5
                    [post_date] => 2020-12-14 14:59:29
                    [post_date_gmt] => 2020-12-14 14:59:29
                    [post_content] => 
                    [post_title] => Sanofi – Translate Bio Collaboration and License Agreement (As Amended)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 11:33:16
                    [post_modified_gmt] => 2021-06-21 11:33:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2422
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [204] => WP_Post Object
                (
                    [ID] => 1395
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:25:33
                    [post_date_gmt] => 2020-05-30 21:25:33
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 08:28:33
                    [post_modified_gmt] => 2020-08-06 08:28:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1395
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [205] => WP_Post Object
                (
                    [ID] => 1394
                    [post_author] => 7
                    [post_date] => 2020-05-30 21:22:44
                    [post_date_gmt] => 2020-05-30 21:22:44
                    [post_content] => 
                    [post_title] => Gates Foundation Sample Terms & Conditions for Project Support Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-sample-terms-conditions-for-project-support-grant-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:20:23
                    [post_modified_gmt] => 2021-06-09 09:20:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1394
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [206] => WP_Post Object
                (
                    [ID] => 1393
                    [post_author] => 7
                    [post_date] => 2020-05-30 20:13:50
                    [post_date_gmt] => 2020-05-30 20:13:50
                    [post_content] => 
                    [post_title] => Gates Foundation Open Access Policy
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 1393
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 15:44:36
                    [post_modified_gmt] => 2021-06-08 15:44:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1393
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [207] => WP_Post Object
                (
                    [ID] => 1315
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:56:03
                    [post_date_gmt] => 2020-05-23 17:56:03
                    [post_content] => 
                    [post_title] => MPP License Agreement with ViiV on Dolutegravir for Adults
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 12:02:04
                    [post_modified_gmt] => 2021-07-21 12:02:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1315
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [208] => WP_Post Object
                (
                    [ID] => 1313
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:55:00
                    [post_date_gmt] => 2020-05-23 17:55:00
                    [post_content] => 
                    [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:26:38
                    [post_modified_gmt] => 2021-07-21 11:26:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1313
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [209] => WP_Post Object
                (
                    [ID] => 1314
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:54:57
                    [post_date_gmt] => 2020-05-23 17:54:57
                    [post_content] => 
                    [post_title] => MPP Amended and Restated Sublicense and Technology Transfer Agreement under BMS-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:28:48
                    [post_modified_gmt] => 2021-07-21 11:28:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1314
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [210] => WP_Post Object
                (
                    [ID] => 1308
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:17:48
                    [post_date_gmt] => 2020-05-23 17:17:48
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 09:45:37
                    [post_modified_gmt] => 2021-06-22 09:45:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1308
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [211] => WP_Post Object
                (
                    [ID] => 1309
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:17:44
                    [post_date_gmt] => 2020-05-23 17:17:44
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking  Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2joint-undertaking-model-consortium-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:28:41
                    [post_modified_gmt] => 2021-06-21 13:28:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1309
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [212] => WP_Post Object
                (
                    [ID] => 1307
                    [post_author] => 7
                    [post_date] => 2020-05-23 17:05:21
                    [post_date_gmt] => 2020-05-23 17:05:21
                    [post_content] => 
                    [post_title] => IMI 2 Model Consortium Agreement & Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:02:13
                    [post_modified_gmt] => 2021-06-21 13:02:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1307
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [213] => WP_Post Object
                (
                    [ID] => 1306
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:57:14
                    [post_date_gmt] => 2020-05-23 16:57:14
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:04:57
                    [post_modified_gmt] => 2021-06-21 13:04:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1306
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [214] => WP_Post Object
                (
                    [ID] => 1305
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:51:40
                    [post_date_gmt] => 2020-05-23 16:51:40
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => 1305
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:23:38
                    [post_modified_gmt] => 2021-06-21 13:23:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1305
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [215] => WP_Post Object
                (
                    [ID] => 1304
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:46:37
                    [post_date_gmt] => 2020-05-23 16:46:37
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:41:52
                    [post_modified_gmt] => 2021-06-21 13:41:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1304
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [216] => WP_Post Object
                (
                    [ID] => 1303
                    [post_author] => 7
                    [post_date] => 2020-05-23 16:46:30
                    [post_date_gmt] => 2020-05-23 16:46:30
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 09:58:35
                    [post_modified_gmt] => 2021-06-22 09:58:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1303
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [217] => WP_Post Object
                (
                    [ID] => 1296
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:46:47
                    [post_date_gmt] => 2020-05-22 23:46:47
                    [post_content] => 
                    [post_title] => Summary of Provisions from WHO Template Agreements
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 11:05:19
                    [post_modified_gmt] => 2021-06-22 11:05:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1296
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [218] => WP_Post Object
                (
                    [ID] => 1291
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:42:19
                    [post_date_gmt] => 2020-05-22 23:42:19
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 11:42:27
                    [post_modified_gmt] => 2021-06-07 11:42:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1291
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [219] => WP_Post Object
                (
                    [ID] => 1293
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:42:02
                    [post_date_gmt] => 2020-05-22 23:42:02
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-15 08:02:02
                    [post_modified_gmt] => 2021-06-15 08:02:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1293
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [220] => WP_Post Object
                (
                    [ID] => 1288
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:31:30
                    [post_date_gmt] => 2020-05-22 23:31:30
                    [post_content] => 
                    [post_title] => IMI 2 Model Consortium Agreement & Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:05:44
                    [post_modified_gmt] => 2021-06-22 08:05:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1288
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [221] => WP_Post Object
                (
                    [ID] => 1287
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:05:30
                    [post_date_gmt] => 2020-05-22 23:05:30
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:02:51
                    [post_modified_gmt] => 2021-07-21 11:02:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1287
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [222] => WP_Post Object
                (
                    [ID] => 1285
                    [post_author] => 6
                    [post_date] => 2020-05-22 23:01:07
                    [post_date_gmt] => 2020-05-22 23:01:07
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:03:29
                    [post_modified_gmt] => 2021-07-21 11:03:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1285
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [223] => WP_Post Object
                (
                    [ID] => 1284
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:58:55
                    [post_date_gmt] => 2020-05-22 22:58:55
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-16 14:49:53
                    [post_modified_gmt] => 2021-06-16 14:49:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1284
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [224] => WP_Post Object
                (
                    [ID] => 1283
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:57:44
                    [post_date_gmt] => 2020-05-22 22:57:44
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:56:15
                    [post_modified_gmt] => 2020-08-06 05:56:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1283
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [225] => WP_Post Object
                (
                    [ID] => 1282
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:56:18
                    [post_date_gmt] => 2020-05-22 22:56:18
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 09:47:34
                    [post_modified_gmt] => 2021-06-01 09:47:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1282
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [226] => WP_Post Object
                (
                    [ID] => 1281
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:55:22
                    [post_date_gmt] => 2020-05-22 22:55:22
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:57:24
                    [post_modified_gmt] => 2020-08-06 05:57:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1281
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [227] => WP_Post Object
                (
                    [ID] => 1280
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:54:32
                    [post_date_gmt] => 2020-05-22 22:54:32
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 08:04:56
                    [post_modified_gmt] => 2021-06-09 08:04:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1280
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [228] => WP_Post Object
                (
                    [ID] => 1276
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:40:34
                    [post_date_gmt] => 2020-05-22 22:40:34
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:03:41
                    [post_modified_gmt] => 2021-07-21 11:03:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1276
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [229] => WP_Post Object
                (
                    [ID] => 1275
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:39:41
                    [post_date_gmt] => 2020-05-22 22:39:41
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 14:18:04
                    [post_modified_gmt] => 2021-05-28 14:18:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1275
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [230] => WP_Post Object
                (
                    [ID] => 1274
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:38:47
                    [post_date_gmt] => 2020-05-22 22:38:47
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 05:59:08
                    [post_modified_gmt] => 2020-08-06 05:59:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1274
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [231] => WP_Post Object
                (
                    [ID] => 1273
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:37:54
                    [post_date_gmt] => 2020-05-22 22:37:54
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-04 04:20:47
                    [post_modified_gmt] => 2020-08-04 04:20:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1273
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [232] => WP_Post Object
                (
                    [ID] => 1272
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:36:39
                    [post_date_gmt] => 2020-05-22 22:36:39
                    [post_content] => 
                    [post_title] => BU Startup Exclusive License
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => bu-startup-exclusive-license-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 10:58:45
                    [post_modified_gmt] => 2021-07-22 10:58:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1272
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [233] => WP_Post Object
                (
                    [ID] => 1271
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:34:12
                    [post_date_gmt] => 2020-05-22 22:34:12
                    [post_content] => 
                    [post_title] => WHO Standard Framework Memorandum of Understanding
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-standard-framework-memorandum-of-understanding-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 10:14:31
                    [post_modified_gmt] => 2021-06-01 10:14:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1271
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [234] => WP_Post Object
                (
                    [ID] => 1270
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:32:29
                    [post_date_gmt] => 2020-05-22 22:32:29
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-10-18 11:46:22
                    [post_modified_gmt] => 2020-10-18 11:46:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1270
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [235] => WP_Post Object
                (
                    [ID] => 1269
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:29:54
                    [post_date_gmt] => 2020-05-22 22:29:54
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:01:05
                    [post_modified_gmt] => 2020-08-06 06:01:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1269
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [236] => WP_Post Object
                (
                    [ID] => 1268
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:27:54
                    [post_date_gmt] => 2020-05-22 22:27:54
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 10:42:12
                    [post_modified_gmt] => 2021-06-22 10:42:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1268
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [237] => WP_Post Object
                (
                    [ID] => 1267
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:26:39
                    [post_date_gmt] => 2020-05-22 22:26:39
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:18:15
                    [post_modified_gmt] => 2021-07-21 11:18:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1267
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [238] => WP_Post Object
                (
                    [ID] => 1266
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:25:16
                    [post_date_gmt] => 2020-05-22 22:25:16
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:00:55
                    [post_modified_gmt] => 2021-06-22 08:00:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1266
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [239] => WP_Post Object
                (
                    [ID] => 1265
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:24:11
                    [post_date_gmt] => 2020-05-22 22:24:11
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 11:02:34
                    [post_modified_gmt] => 2021-06-01 11:02:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1265
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [240] => WP_Post Object
                (
                    [ID] => 1264
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:22:55
                    [post_date_gmt] => 2020-05-22 22:22:55
                    [post_content] => 
                    [post_title] => Gilead HCV License Agreement with Indian Generic Manufacturers
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gilead-hcv-license-agreement-with-indian-generic-manufacturers-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 11:09:14
                    [post_modified_gmt] => 2021-05-28 11:09:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1264
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [241] => WP_Post Object
                (
                    [ID] => 1263
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:20:56
                    [post_date_gmt] => 2020-05-22 22:20:56
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:56:20
                    [post_modified_gmt] => 2021-07-21 11:56:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1263
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [242] => WP_Post Object
                (
                    [ID] => 1262
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:18:41
                    [post_date_gmt] => 2020-05-22 22:18:41
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 11:05:58
                    [post_modified_gmt] => 2021-06-07 11:05:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1262
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [243] => WP_Post Object
                (
                    [ID] => 1261
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:17:34
                    [post_date_gmt] => 2020-05-22 22:17:34
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:02:17
                    [post_modified_gmt] => 2021-06-22 08:02:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1261
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [244] => WP_Post Object
                (
                    [ID] => 1259
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:04:31
                    [post_date_gmt] => 2020-05-22 22:04:31
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:06:50
                    [post_modified_gmt] => 2020-08-06 06:06:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1259
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [245] => WP_Post Object
                (
                    [ID] => 1258
                    [post_author] => 6
                    [post_date] => 2020-05-22 22:03:08
                    [post_date_gmt] => 2020-05-22 22:03:08
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-22 14:03:39
                    [post_modified_gmt] => 2021-07-22 14:03:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1258
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [246] => WP_Post Object
                (
                    [ID] => 1257
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:54:08
                    [post_date_gmt] => 2020-05-22 21:54:08
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 10:59:58
                    [post_modified_gmt] => 2021-06-07 10:59:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1257
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [247] => WP_Post Object
                (
                    [ID] => 1255
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:49:26
                    [post_date_gmt] => 2020-05-22 21:49:26
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 11:56:13
                    [post_modified_gmt] => 2021-06-17 11:56:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1255
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [248] => WP_Post Object
                (
                    [ID] => 1254
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:44:49
                    [post_date_gmt] => 2020-05-22 21:44:49
                    [post_content] => 
                    [post_title] => Gates Foundation Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-foundation-data-materials-sharing-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:09:56
                    [post_modified_gmt] => 2020-08-06 06:09:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1254
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [249] => WP_Post Object
                (
                    [ID] => 1253
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:42:28
                    [post_date_gmt] => 2020-05-22 21:42:28
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:08:14
                    [post_modified_gmt] => 2021-06-22 08:08:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1253
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [250] => WP_Post Object
                (
                    [ID] => 1252
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:41:17
                    [post_date_gmt] => 2020-05-22 21:41:17
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 13:40:39
                    [post_modified_gmt] => 2021-05-28 13:40:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1252
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [251] => WP_Post Object
                (
                    [ID] => 1251
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:39:48
                    [post_date_gmt] => 2020-05-22 21:39:48
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:40:50
                    [post_modified_gmt] => 2020-08-06 19:40:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1251
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [252] => WP_Post Object
                (
                    [ID] => 1250
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:38:31
                    [post_date_gmt] => 2020-05-22 21:38:31
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-2-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 19:41:55
                    [post_modified_gmt] => 2020-08-06 19:41:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1250
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [253] => WP_Post Object
                (
                    [ID] => 1249
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:37:42
                    [post_date_gmt] => 2020-05-22 21:37:42
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:22:26
                    [post_modified_gmt] => 2020-08-06 06:22:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1249
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [254] => WP_Post Object
                (
                    [ID] => 1248
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:36:47
                    [post_date_gmt] => 2020-05-22 21:36:47
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:19:18
                    [post_modified_gmt] => 2020-08-06 06:19:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1248
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [255] => WP_Post Object
                (
                    [ID] => 1247
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:33:54
                    [post_date_gmt] => 2020-05-22 21:33:54
                    [post_content] => 
                    [post_title] => WHO Mutual Confidential Disclosure Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-mutual-confidential-disclosure-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-10 11:25:18
                    [post_modified_gmt] => 2021-06-10 11:25:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1247
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [256] => WP_Post Object
                (
                    [ID] => 1245
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:32:14
                    [post_date_gmt] => 2020-05-22 21:32:14
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 14:50:49
                    [post_modified_gmt] => 2021-06-17 14:50:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1245
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [257] => WP_Post Object
                (
                    [ID] => 1243
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:29:10
                    [post_date_gmt] => 2020-05-22 21:29:10
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:15:56
                    [post_modified_gmt] => 2020-08-06 06:15:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1243
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [258] => WP_Post Object
                (
                    [ID] => 1242
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:26:04
                    [post_date_gmt] => 2020-05-22 21:26:04
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:03:53
                    [post_modified_gmt] => 2021-07-21 11:03:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1242
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [259] => WP_Post Object
                (
                    [ID] => 1240
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:22:47
                    [post_date_gmt] => 2020-05-22 21:22:47
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 18:39:45
                    [post_modified_gmt] => 2021-06-01 18:39:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1240
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [260] => WP_Post Object
                (
                    [ID] => 1239
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:21:49
                    [post_date_gmt] => 2020-05-22 21:21:49
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-07 13:42:45
                    [post_modified_gmt] => 2021-06-07 13:42:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1239
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [261] => WP_Post Object
                (
                    [ID] => 1238
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:20:51
                    [post_date_gmt] => 2020-05-22 21:20:51
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 14:00:56
                    [post_modified_gmt] => 2021-06-08 14:00:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1238
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [262] => WP_Post Object
                (
                    [ID] => 1237
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:19:08
                    [post_date_gmt] => 2020-05-22 21:19:08
                    [post_content] => 
                    [post_title] => IMI 2 Joint Undertaking Model Consortium Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-joint-undertaking-model-consortium-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 13:10:16
                    [post_modified_gmt] => 2021-06-21 13:10:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1237
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [263] => WP_Post Object
                (
                    [ID] => 1235
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:01:14
                    [post_date_gmt] => 2020-05-22 21:01:14
                    [post_content] => 
                    [post_title] => Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-21 11:04:08
                    [post_modified_gmt] => 2021-07-21 11:04:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1235
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [264] => WP_Post Object
                (
                    [ID] => 1233
                    [post_author] => 6
                    [post_date] => 2020-05-22 21:00:08
                    [post_date_gmt] => 2020-05-22 21:00:08
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 13:58:18
                    [post_modified_gmt] => 2021-06-08 13:58:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1233
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [265] => WP_Post Object
                (
                    [ID] => 1232
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:57:46
                    [post_date_gmt] => 2020-05-22 20:57:46
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 09:30:36
                    [post_modified_gmt] => 2021-06-21 09:30:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1232
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [266] => WP_Post Object
                (
                    [ID] => 1231
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:54:50
                    [post_date_gmt] => 2020-05-22 20:54:50
                    [post_content] => 
                    [post_title] => CAVD Data & Materials Sharing Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cavd-data-materials-sharing-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-08-06 06:37:41
                    [post_modified_gmt] => 2020-08-06 06:37:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1231
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [267] => WP_Post Object
                (
                    [ID] => 1229
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:51:35
                    [post_date_gmt] => 2020-05-22 20:51:35
                    [post_content] => 
                    [post_title] => MPP License Agreement with BMS & Aurobindo Pharma Ltd.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 11:52:06
                    [post_modified_gmt] => 2021-06-21 11:52:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1229
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [268] => WP_Post Object
                (
                    [ID] => 1228
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:49:20
                    [post_date_gmt] => 2020-05-22 20:49:20
                    [post_content] => 
                    [post_title] => MPP License Agreement with Gilead
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-gilead-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 12:03:38
                    [post_modified_gmt] => 2021-06-21 12:03:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1228
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [269] => WP_Post Object
                (
                    [ID] => 1227
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:48:27
                    [post_date_gmt] => 2020-05-22 20:48:27
                    [post_content] => 
                    [post_title] => Ebola WHO-Manufacturer LOA (Annex)
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => ebola-who-manufacturer-loa-annex
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-06 13:55:12
                    [post_modified_gmt] => 2021-07-06 13:55:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1227
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [270] => WP_Post Object
                (
                    [ID] => 1226
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:47:05
                    [post_date_gmt] => 2020-05-22 20:47:05
                    [post_content] => 
                    [post_title] => WHO Template Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-21 09:49:13
                    [post_modified_gmt] => 2021-06-21 09:49:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1226
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [271] => WP_Post Object
                (
                    [ID] => 1225
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:43:20
                    [post_date_gmt] => 2020-05-22 20:43:20
                    [post_content] => 
                    [post_title] => WHO Template Material Transfer Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => who-template-material-transfer-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-10 12:10:21
                    [post_modified_gmt] => 2021-06-10 12:10:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1225
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [272] => WP_Post Object
                (
                    [ID] => 1222
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:12:04
                    [post_date_gmt] => 2020-05-22 20:12:04
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 12:52:26
                    [post_modified_gmt] => 2021-06-17 12:52:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1222
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [273] => WP_Post Object
                (
                    [ID] => 1221
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:09:53
                    [post_date_gmt] => 2020-05-22 20:09:53
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 15:41:03
                    [post_modified_gmt] => 2021-06-08 15:41:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [274] => WP_Post Object
                (
                    [ID] => 1220
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:05:59
                    [post_date_gmt] => 2020-05-22 20:05:59
                    [post_content] => 
                    [post_title] => Redacted Collaboration Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => redacted-collaboration-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 15:06:36
                    [post_modified_gmt] => 2021-05-28 15:06:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [275] => WP_Post Object
                (
                    [ID] => 1218
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:04:53
                    [post_date_gmt] => 2020-05-22 20:04:53
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 15:32:44
                    [post_modified_gmt] => 2021-06-08 15:32:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [276] => WP_Post Object
                (
                    [ID] => 1217
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:00:26
                    [post_date_gmt] => 2020-05-22 20:00:26
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:34:18
                    [post_modified_gmt] => 2021-06-09 09:34:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [277] => WP_Post Object
                (
                    [ID] => 1216
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:58:08
                    [post_date_gmt] => 2020-05-22 19:58:08
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:19:32
                    [post_modified_gmt] => 2021-06-09 09:19:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [278] => WP_Post Object
                (
                    [ID] => 1215
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:56:47
                    [post_date_gmt] => 2020-05-22 19:56:47
                    [post_content] => 
                    [post_title] => EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => edctp2-policy-on-clinical-trials-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-08 15:42:31
                    [post_modified_gmt] => 2021-06-08 15:42:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [279] => WP_Post Object
                (
                    [ID] => 1214
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:55:41
                    [post_date_gmt] => 2020-05-22 19:55:41
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 09:21:17
                    [post_modified_gmt] => 2021-06-09 09:21:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1214
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [280] => WP_Post Object
                (
                    [ID] => 1211
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:50:22
                    [post_date_gmt] => 2020-05-22 19:50:22
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 10:55:06
                    [post_modified_gmt] => 2021-06-22 10:55:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1211
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [281] => WP_Post Object
                (
                    [ID] => 1207
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:42:36
                    [post_date_gmt] => 2020-05-22 19:42:36
                    [post_content] => 
                    [post_title] => MPP License Agreement with Pfizer re Sutezolid
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-pfizer-re-sutezolid
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 08:38:47
                    [post_modified_gmt] => 2021-07-07 08:38:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1207
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [282] => WP_Post Object
                (
                    [ID] => 1206
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:37:27
                    [post_date_gmt] => 2020-05-22 19:37:27
                    [post_content] => 
                    [post_title] => Gates Global Access Commitment & Humanitarian License
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gates-global-access-commitment-and-humanitarian-license
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-11 14:17:10
                    [post_modified_gmt] => 2021-06-11 14:17:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [283] => WP_Post Object
                (
                    [ID] => 1200
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:35:05
                    [post_date_gmt] => 2020-05-22 19:35:05
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:30:10
                    [post_modified_gmt] => 2021-07-07 16:30:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [284] => WP_Post Object
                (
                    [ID] => 1205
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:33:17
                    [post_date_gmt] => 2020-05-22 19:33:17
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:22:22
                    [post_modified_gmt] => 2021-07-07 16:22:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [285] => WP_Post Object
                (
                    [ID] => 1204
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:31:46
                    [post_date_gmt] => 2020-05-22 19:31:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:23:03
                    [post_modified_gmt] => 2021-07-07 16:23:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [286] => WP_Post Object
                (
                    [ID] => 1203
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:30:52
                    [post_date_gmt] => 2020-05-22 19:30:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:21:41
                    [post_modified_gmt] => 2021-07-07 16:21:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [287] => WP_Post Object
                (
                    [ID] => 1202
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:28:49
                    [post_date_gmt] => 2020-05-22 19:28:49
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:27:22
                    [post_modified_gmt] => 2021-07-07 16:27:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [288] => WP_Post Object
                (
                    [ID] => 1201
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:26:29
                    [post_date_gmt] => 2020-05-22 19:26:29
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 16:29:47
                    [post_modified_gmt] => 2021-07-07 16:29:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [289] => WP_Post Object
                (
                    [ID] => 1199
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:21:57
                    [post_date_gmt] => 2020-05-22 19:21:57
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-11 08:35:03
                    [post_modified_gmt] => 2021-06-11 08:35:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [290] => WP_Post Object
                (
                    [ID] => 1198
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:12:54
                    [post_date_gmt] => 2020-05-22 19:12:54
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-11 08:23:10
                    [post_modified_gmt] => 2021-06-11 08:23:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1198
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [291] => WP_Post Object
                (
                    [ID] => 1190
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:59:48
                    [post_date_gmt] => 2020-05-22 01:59:48
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-07-07 13:58:32
                    [post_modified_gmt] => 2021-07-07 13:58:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [292] => WP_Post Object
                (
                    [ID] => 1187
                    [post_author] => 6
                    [post_date] => 2020-05-22 01:56:10
                    [post_date_gmt] => 2020-05-22 01:56:10
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 08:56:00
                    [post_modified_gmt] => 2021-06-01 08:56:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [293] => WP_Post Object
                (
                    [ID] => 1186
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:11:20
                    [post_date_gmt] => 2020-05-22 00:11:20
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 07:56:15
                    [post_modified_gmt] => 2021-06-09 07:56:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1186
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [294] => WP_Post Object
                (
                    [ID] => 1185
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:10:01
                    [post_date_gmt] => 2020-05-22 00:10:01
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 12:20:34
                    [post_modified_gmt] => 2021-06-17 12:20:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1185
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [295] => WP_Post Object
                (
                    [ID] => 1184
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:08:17
                    [post_date_gmt] => 2020-05-22 00:08:17
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-15 07:52:40
                    [post_modified_gmt] => 2021-06-15 07:52:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1184
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [296] => WP_Post Object
                (
                    [ID] => 1183
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:06:26
                    [post_date_gmt] => 2020-05-22 00:06:26
                    [post_content] => 
                    [post_title] => MPP Sublicense Agreement under AbbVie-MPP License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-license-agreement-with-abbvie
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-11 07:31:18
                    [post_modified_gmt] => 2021-06-11 07:31:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1183
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [297] => WP_Post Object
                (
                    [ID] => 1182
                    [post_author] => 6
                    [post_date] => 2020-05-22 00:02:42
                    [post_date_gmt] => 2020-05-22 00:02:42
                    [post_content] => 
                    [post_title] => AUTM Model Inter-Institutional Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => autm-model-iia-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-09 07:52:45
                    [post_modified_gmt] => 2021-06-09 07:52:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1182
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [298] => WP_Post Object
                (
                    [ID] => 1178
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:55:50
                    [post_date_gmt] => 2020-05-21 23:55:50
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 09:31:51
                    [post_modified_gmt] => 2021-06-22 09:31:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [299] => WP_Post Object
                (
                    [ID] => 1177
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:53:56
                    [post_date_gmt] => 2020-05-21 23:53:56
                    [post_content] => 
                    [post_title] => Lambert Agreement D
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => lambert-agreement-d-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 13:50:50
                    [post_modified_gmt] => 2021-05-28 13:50:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1177
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [300] => WP_Post Object
                (
                    [ID] => 1176
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:52:12
                    [post_date_gmt] => 2020-05-21 23:52:12
                    [post_content] => 
                    [post_title] => Aridis-PATH Vaccine Formulation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => aridis-path-vaccine-formulation-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 14:16:14
                    [post_modified_gmt] => 2021-05-28 14:16:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1176
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [301] => WP_Post Object
                (
                    [ID] => 1175
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:44:57
                    [post_date_gmt] => 2020-05-21 23:44:57
                    [post_content] => 
                    [post_title] => Funder Development Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => funder-development-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-05-28 14:26:08
                    [post_modified_gmt] => 2021-05-28 14:26:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1175
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [302] => WP_Post Object
                (
                    [ID] => 1173
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:37:42
                    [post_date_gmt] => 2020-05-21 23:37:42
                    [post_content] => 
                    [post_title] => CARB-X Research Subaward Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => carb-x-research-subaward-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-01 17:20:05
                    [post_modified_gmt] => 2021-06-01 17:20:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1173
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [303] => WP_Post Object
                (
                    [ID] => 1172
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:35:57
                    [post_date_gmt] => 2020-05-21 23:35:57
                    [post_content] => 
                    [post_title] => IMI 2 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-2-model-grant-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-22 08:53:37
                    [post_modified_gmt] => 2021-06-22 08:53:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1172
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [304] => WP_Post Object
                (
                    [ID] => 1171
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:33:24
                    [post_date_gmt] => 2020-05-21 23:33:24
                    [post_content] => 
                    [post_title] => IMI 1 Model Grant Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => imi-1-model-grant-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-06-17 14:23:00
                    [post_modified_gmt] => 2021-06-17 14:23:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1171
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [305] => WP_Post Object
                (
                    [ID] => 1170
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:28:59
                    [post_date_gmt] => 2020-05-21 23:28:59
                    [post_content] =>